

Liver cirrhosis

Lancet, The

383, 1749-1761

DOI: 10.1016/s0140-6736(14)60121-5

Citation Report

#	ARTICLE	IF	CITATIONS
1	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE, 2014, 9, e108544.	1.1	29
2	Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy. Annals of Hepatology, 2014, 13, 555-557.	0.6	2
3	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. Seminars in Liver Disease, 2014, 34, 444-455.	1.8	112
4	Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. Journal of Integrative Medicine, 2014, 12, 401-408.	1.4	94
5	Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2014, 11, 525-535.	12.5	377
6	Prognosis prediction and staging. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 855-865.	1.0	20
7	Beta-blockers in cirrhosis: Therapeutic window or an aspirin for all?. Journal of Hepatology, 2014, 61, 449-450.	1.8	12
8	Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C. The Cochrane Library, 0, , .	1.5	2
10	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. More doubts than clarity. Hepatology, 2015, 62, 976-977.	3.6	11
11	Hyponatremia: a significant factor in a poor prognosis for cirrhosis with Child A/B after variceal eradication. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 771-778.	1.4	1
12	Should surgery be carried out in patients with hepatocellular carcinoma with portal hypertension?. Hepatology, 2015, 62, 976-976.	3.6	5
13	Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1635-1642.	1.4	3
14	Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma. Liver International, 2015, 35, 2327-2336.	1.9	55
15	Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. Journal of Digestive Diseases, 2015, 16, 665-674.	0.7	11
16	Assessing liver disease in HIV-HCV coinfecting patients. Current Opinion in HIV and AIDS, 2015, 10, 316-322.	1.5	8
17	A new model combining the liver/spleen volume ratio and classification of varices predicts HVPG in hepatitis B patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2015, 27, 335-343.	0.8	23
18	Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World Journal of Hepatology, 2015, 7, 688.	0.8	52
19	Liver lobe-based magnetic resonance diffusion-weighted imaging using multiple b values in patients with hepatitis B-related liver cirrhosis: association with the liver disease severity according to the Child-Pugh class. Clinics, 2015, 70, 486-492.	0.6	0

#	ARTICLE	IF	CITATIONS
20	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11044.	1.4	25
21	Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. <i>World Journal of Gastroenterology</i> , 2015, 21, 11552.	1.4	48
22	Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. <i>World Journal of Hepatology</i> , 2015, 7, 607.	0.8	52
23	Acute kidney injury in patients with chronic liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 993.	0.8	15
24	Lack of the Lysosomal Membrane Protein, GLMP, in Mice Results in Metabolic Dysregulation in Liver. <i>PLoS ONE</i> , 2015, 10, e0129402.	1.1	10
25	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	41
26	The Value of Circulating Nogo-B for Evaluating Hepatic Functional Reserve in Patients with Cirrhosis. <i>Disease Markers</i> , 2015, 2015, 1-6.	0.6	7
27	Association between Portal Vein Thrombosis and Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the Literature. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	0.7	28
28	Neutrophil Gelatinase-Associated Lipocalin: A New Marker of Renal Function in C-Related End Stage Liver Disease. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	11
29	Molecular prognostic prediction in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 10262.	1.4	12
30	Management before hepatectomy for hepatocellular carcinoma with cirrhosis. <i>World Journal of Hepatology</i> , 2015, 7, 2292.	0.8	13
31	Prognosis of Early-Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1929.	0.4	32
32	Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Liver Fibrosis in Rats. <i>Transplantation Direct</i> , 2015, 1, 1-9.	0.8	37
33	Association between lymphocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: a retrospective cohort study. <i>BMJ Open</i> , 2015, 5, e008033.	0.8	24
34	TNF $\alpha$ in Liver Fibrosis. <i>Current Pathobiology Reports</i> , 2015, 3, 253-261.	1.6	141
36	Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 309-327.	1.9	25
37	Synthesis and application of strawberry-like Fe <sub>3</sub> O <sub>4</sub> -Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease. <i>Biomaterials</i> , 2015, 51, 194-207.	5.7	93
38	Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 739-744.	1.8	24

#	ARTICLE	IF	CITATIONS
40	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. <i>Current Hepatology Reports</i> , 2015, 14, 32-39.	0.4	0
41	MicroRNAs in Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 012-025.	1.8	35
42	Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. <i>International Journal of Infectious Diseases</i> , 2015, 33, 149-155.	1.5	21
43	A Multilevel Modeling Framework to Study Hepatic Perfusion Characteristics in Case of Liver Cirrhosis. <i>Journal of Biomechanical Engineering</i> , 2015, 137, 051007.	0.6	29
44	Understanding the Complexities of Cirrhosis. <i>Clinical Therapeutics</i> , 2015, 37, 1822-1836.	1.1	37
45	Role of NADPH oxidases in the redox biology of liver fibrosis. <i>Redox Biology</i> , 2015, 6, 106-111.	3.9	127
46	Endothelin 1 and transforming growth factor- $\beta$ 1 correlate with liver function and portal pressure in cirrhotic patients. <i>Cytokine</i> , 2015, 76, 144-151.	1.4	9
47	Pathophysiology and a Rational Basis of Therapy. <i>Digestive Diseases</i> , 2015, 33, 508-514.	0.8	17
48	Clinical Evaluation and Prognosis. <i>Digestive Diseases</i> , 2015, 33, 515-523.	0.8	10
49	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	1.8	239
50	Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 541-548.	1.4	19
51	Complications of cirrhosis. A 50 years flashback. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 763-780.	0.6	19
52	New cellular and molecular targets for the treatment of portal hypertension. <i>Hepatology International</i> , 2015, 9, 183-191.	1.9	48
53	Influence of splenorenal shunt on long-term outcomes in cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 593-600.	0.6	15
54	Global Epidemiology of Hepatitis B Virus (HBV) Infection. <i>Current Hepatology Reports</i> , 2015, 14, 171-178.	0.4	31
55	Primary Care Management of Alcohol Misuse. <i>Medical Clinics of North America</i> , 2015, 99, 989-1016.	1.1	8
56	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015, 64, 1434-1443.	6.1	159
57	R-spondin1 arguments hepatic fibrogenesis in vivo and in vitro. <i>Journal of Surgical Research</i> , 2015, 193, 598-605.	0.8	12

#	ARTICLE	IF	CITATIONS
58	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	3.6	286
59	DIETARY MANAGEMENT FOR DYSLIPIDEMIA IN LIVER TRANSPLANT RECIPIENTS. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2016, 29, 246-251.	0.5	8
60	Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases. <i>Clinical and Experimental Hepatology</i> , 2016, 4, 149-154.	0.6	1
61	Cirrhosis and autoimmune liver disease: Current understanding. <i>World Journal of Hepatology</i> , 2016, 8, 1157.	0.8	47
62	The Role of Physical Activity and Nutrition in the Sarcopenia of Cirrhosis. <i>Journal of Functional Morphology and Kinesiology</i> , 2016, 1, 118-125.	1.1	12
63	Altered Doppler flow patterns in cirrhosis patients: an overview. <i>Ultrasonography</i> , 2016, 35, 3-12.	1.0	70
64	Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 139-148.	3.0	7
65	Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis. <i>World Journal of Hepatology</i> , 2016, 8, 739.	0.8	10
66	High serum ferritin is associated with worse outcome of patients with decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2016, 30, 217-224.	0.4	14
67	New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 166-178.	0.2	38
68	Ethyl Acetate Fraction of <i>Amomum xanthioides</i> Exerts Antihepatofibrotic Actions via the Regulation of Fibrogenic Cytokines in a Dimethylnitrosamine-Induced Rat Model. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-14.	0.5	9
69	Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-5.	0.7	37
70	Comparison of the Treatment Efficiency of Bone Marrow-Derived Mesenchymal Stem Cell Transplantation via Tail and Portal Veins in CCl <sub>4</sub> -Induced Mouse Liver Fibrosis. <i>Stem Cells International</i> , 2016, 2016, 1-13.	1.2	28
71	Down-Regulation of NFκB, Bax, TGF-β <sub>2</sub> , Smad-2 mRNA expression in the Livers of Carbon Tetrachloride Treated Rats using Different Natural Antioxidants. <i>Brazilian Archives of Biology and Technology</i> , 2016, 59, .	0.5	9
72	The Relationship between Serum Bilirubin and Elevated Fibrotic Indices among HBV Carriers: A Cross-Sectional Study of a Chinese Population. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2057.	1.8	12
73	Morphological and Functional Aspects of Human Skeletal Muscle. <i>Journal of Functional Morphology and Kinesiology</i> , 2016, 1, 289-302.	1.1	27
74	Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. <i>PLoS ONE</i> , 2016, 11, e0141159.	1.1	17
75	The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts. <i>Frontiers in Physiology</i> , 2016, 7, 17.	1.3	152

#	ARTICLE	IF	CITATIONS
76	Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease. <i>Medicine (United States)</i> , 2016, 95, 105-112.	0.4	20
77	Well-tolerated portal hypertension and favorable prognosis in adult patients with extrahepatic portal vein obstruction in Japan. <i>Hepatology Research</i> , 2016, 46, 505-513.	1.8	4
78	Influence of CYP2D6 and $\beta_2$ -adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 829-834.	1.4	9
79	Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. <i>Liver International</i> , 2016, 36, 1313-1321.	1.9	29
80	A non-invasive magnetic resonance imaging-based model predicts portal venous pressure. <i>Journal of Digestive Diseases</i> , 2016, 17, 175-185.	0.7	7
81	Portal response related to shunt occlusion by balloon-occluded retrograde transvenous obliteration may determine the prognosis of cirrhosis. <i>Hepatology Research</i> , 2016, 46, 1321-1329.	1.8	3
82	How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures?. <i>Transfusion</i> , 2016, 56, 791-798.	0.8	14
83	Why is viral eradication so important in patients with HCV-related cirrhosis?. <i>Antiviral Therapy</i> , 2016, 22, 1-12.	0.6	9
84	Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. <i>BMJ Open</i> , 2016, 6, e012991.	0.8	30
86	Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e3853.	0.4	38
87	A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis. <i>Scientific Reports</i> , 2016, 6, 19903.	1.6	56
88	Hemodynamic effect of the left gastric artery on esophageal varices in patients with cirrhosis. <i>Journal of Gastroenterology</i> , 2016, 51, 900-909.	2.3	5
89	Hepatic IGF-1R overexpression combined with the activation of GSK-3 $\beta$ and FOXO3a in the development of liver cirrhosis. <i>Life Sciences</i> , 2016, 147, 97-102.	2.0	13
90	A synthetic biology-based device prevents liver injury in mice. <i>Journal of Hepatology</i> , 2016, 65, 84-94.	1.8	47
91	Interleukin-13 is involved in the formation of liver fibrosis in <i>Clonorchis sinensis</i> -infected mice. <i>Parasitology Research</i> , 2016, 115, 2653-2660.	0.6	18
92	Natural History of Patients Taking Rifaximin for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. <i>Clinical Therapeutics</i> , 2016, 38, 1081-1089.e4.	1.1	13
93	Bioinformatics microarray analysis and identification of gene expression profiles associated with cirrhotic liver. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 165-176.	0.8	13
94	Implications and benefits of the use of rifaximin for preventing episodes of hepatic encephalopathy. <i>British Journal of Health Care Management</i> , 2016, 22, 108-111.	0.1	1

#	ARTICLE	IF	CITATIONS
95	Towards a unified approach in the modeling of fibrosis: A review with research perspectives. <i>Physics of Life Reviews</i> , 2016, 17, 61-85.	1.5	45
96	Predisposing Factors in Acute-on-Chronic Liver Failure. <i>Seminars in Liver Disease</i> , 2016, 36, 167-173.	1.8	28
97	Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e359.	2.3	10
98	Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. <i>Hpb</i> , 2016, 18, 678-683.	0.1	19
99	Predictive value of exhaled nitric oxide and aerobic capacity for sepsis complications after liver transplantation. <i>Transplant International</i> , 2016, 29, 1307-1316.	0.8	6
100	Hepatorenal Syndrome: Diagnosis and Treatment "newsreel". <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2016, 54, 143-150.	0.3	2
101	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. <i>Chemical Research in Toxicology</i> , 2016, 29, 1936-1955.	1.7	196
102	Targeting the transsulfuration-H <sub>2</sub> S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. <i>Pharmacological Research</i> , 2016, 111, 749-756.	3.1	14
103	Novel matrine derivative MD-1 attenuates hepatic fibrosis by inhibiting EGFR activation of hepatic stellate cells. <i>Protein and Cell</i> , 2016, 7, 662-672.	4.8	36
104	Immunosuppressive Medication Adherence in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2016, 48, 1198-1201.	0.3	15
105	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. <i>Journal of Viral Hepatitis</i> , 2016, 23, 139-149.	1.0	17
106	Intrahepatic NK cells function suppressed in advanced liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 864-872.	1.7	19
107	Succinct guide to liver transplantation for medical students. <i>Annals of Medicine and Surgery</i> , 2016, 12, 47-53.	0.5	4
108	SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. <i>Scientific Reports</i> , 2016, 5, 17701.	1.6	31
109	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. <i>Exposure and Health</i> , 2016, , 1-22.	2.8	0
110	Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e180.	1.3	103
111	Two-dimensional shear wave elastography with propagation-based reliability assessment for grading hepatic fibrosis and portal hypertension. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 595-602.	1.4	21
112	Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 948-954.	0.8	31

#	ARTICLE	IF	CITATIONS
113	MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. <i>Toxicology Letters</i> , 2016, 258, 159-167.	0.4	23
114	Hepatorenal syndrome: a nurse's guide to identification, management and advocacy. <i>Gastrointestinal Nursing</i> , 2016, 14, S12-S18.	0.0	0
115	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. <i>Scientific Reports</i> , 2016, 6, 32341.	1.6	101
116	Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. <i>Medicine (United States)</i> , 2016, 95, e2946.	0.4	11
117	Transfusion strategies in patients with cirrhosis: less is more. <i>Liver International</i> , 2016, 36, 503-504.	1.9	13
118	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. <i>Internal and Emergency Medicine</i> , 2016, 11, 905-916.	1.0	9
119	Age-dependent development of liver fibrosis in Glmp gt/gt mice. <i>Fibrogenesis and Tissue Repair</i> , 2016, 9, 5.	3.4	7
121	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. <i>Journal of Hepatology</i> , 2016, 65, 1217-1231.	1.8	96
122	The ischemic liver cirrhosis theory and its clinical implications. <i>Medical Hypotheses</i> , 2016, 94, 4-6.	0.8	20
123	AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e2946.	0.4	11
124	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
125	The rationale for targeting <sc>TGF</sc>â€² in chronic liver diseases. <i>European Journal of Clinical Investigation</i> , 2016, 46, 349-361.	1.7	60
126	Liver Fibrosis Staging with MR Elastography: Comparison of Diagnostic Performance between Patients with Chronic Hepatitis B and Those with Other Etiologic Causes. <i>Radiology</i> , 2016, 280, 88-97.	3.6	54
127	The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 141, 584-594.	2.5	27
128	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 197-202.	0.4	14
129	MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. <i>European Journal of Radiology</i> , 2016, 85, 546-552.	1.2	19
130	Fontan-associated liver disease: Implications for heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 26-33.	0.3	101
131	Selected Noninvasive Markers in Diagnosing Liver Diseases. <i>Laboratory Medicine</i> , 2016, 47, 67-72.	0.8	1



#	ARTICLE	IF	CITATIONS
132	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. <i>Advances in Therapy</i> , 2016, 33, 291-319.	1.3	62
133	New Targets in Therapy: Statins, Antioxidants and Antiangiogenic Strategies. , 2016, , 127-133.		0
134	Etiological Treatments: Lifestyle Management. , 2016, , 105-110.		0
135	Portal Hypertension VI. , 2016, , .		27
136	Morphologic severity of cirrhosis determines the extent of liver resection in patients with hepatocellular carcinoma and Child-Pugh grade AA cirrhosis. <i>Journal of Surgical Research</i> , 2016, 200, 444-451.	0.8	18
137	Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. <i>Journal of Hepatology</i> , 2016, 64, 618-627.	1.8	88
138	Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 113-121.	2.9	236
139	A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease. <i>Journal of Pharmacy Practice</i> , 2017, 30, 58-63.	0.5	25
140	Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H21-H32.	1.5	38
141	Systematic quantification of histological patterns shows accuracy in reflecting cirrhotic remodeling. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1631-1639.	1.4	5
142	Diagnosis and treatment of ascites. <i>Journal of Hepatology</i> , 2017, 67, 184-185.	1.8	24
143	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. <i>Scientific Reports</i> , 2017, 7, 40556.	1.6	10
144	Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. <i>American Journal of Gastroenterology</i> , 2017, 112, 588-596.	0.2	82
145	The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 986-992.	1.6	50
146	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42577.	1.6	25
147	Phase-contrast MR flow imaging: A tool to determine hepatic hemodynamics in rats with a healthy, fibrotic, or cirrhotic liver. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1526-1534.	1.9	2
148	Non-invasive evaluation of portal hypertension using ultrasound elastography. <i>Journal of Hepatology</i> , 2017, 67, 399-411.	1.8	211
149	Diagnosis and evaluation of hyperbilirubinemia. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 164-170.	1.0	44

#	ARTICLE	IF	CITATIONS
150	Cirrhosis and portal hypertension. , 2017, , 1148-1160.e2.		0
151	Mortalidad hospitalaria en pacientes cirrÃ3ticos en un hospital de tercer nivel. Revista De GastroenterologÃa De MÃ©xico, 2017, 82, 203-209.	0.4	11
152	Hepatic stellate cells as key target in liver fibrosis. Advanced Drug Delivery Reviews, 2017, 121, 27-42.	6.6	943
153	Liver-to-abdominal area ratio for predicting the in-hospital mortality in advanced liver cirrhosis. Postgraduate Medicine, 2017, 129, 756-761.	0.9	4
154	Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. CardioVascular and Interventional Radiology, 2017, 40, 1372-1382.	0.9	22
155	Developmental Signaling and Organ Fibrosis. Current Pathobiology Reports, 2017, 5, 133-143.	1.6	4
156	Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. Aids, 2017, 31, 493-500.	1.0	22
157	Combined spontaneous bacterial empyema and peritonitis in cirrhotic patients with ascites and hepatic hydrothorax. Arab Journal of Gastroenterology, 2017, 18, 104-107.	0.4	11
158	Flow dynamics analyses of pathophysiological liver lobules using porous media theory. Acta Mechanica Sinica/Lixue Xuebao, 2017, 33, 823-832.	1.5	24
159	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology, 2017, 285, 670-680.	3.6	88
160	Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts via activation of the Hedgehog signaling pathway. Cell Cycle, 2017, 16, 1357-1365.	1.3	9
161	Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Advanced Drug Delivery Reviews, 2017, 121, 3-8.	6.6	119
162	Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. Journal of Translational Medicine, 2017, 15, 75.	1.8	39
163	Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis. Annals of Intensive Care, 2017, 7, 33.	2.2	77
164	Selective inhibitor of Wnt/ $\beta$ -catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model. Scientific Reports, 2017, 7, 325.	1.6	62
165	C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 472-480.	0.8	18
166	Rationale for the use of statins in liver disease. American Journal of Physiology - Renal Physiology, 2017, 312, G407-G412.	1.6	52
167	Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver International, 2017, 37, 1334-1344.	1.9	33

#	ARTICLE	IF	CITATIONS
168	EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portosystemic shunt?. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 248-249.	0.5	6
169	Factors affecting the postoperative morbidity and survival of patients with liver cirrhosis following colorectal cancer surgery. <i>International Journal of Colorectal Disease</i> , 2017, 32, 521-530.	1.0	17
170	The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats. <i>Ultrastructural Pathology</i> , 2017, 41, 23-35.	0.4	6
171	Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. <i>Journal of Surgical Research</i> , 2017, 210, 99-107.	0.8	19
172	Mesenchymal Stem Cell Therapy for Liver Cirrhosis Treatment: Mechanisms and Bioeffects. <i>Stem Cells in Clinical Applications</i> , 2017, , 51-66.	0.4	0
173	Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic <scp>HBV</scp> infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 57-65.	1.0	26
174	Autophagy mediated by endoplasmic reticulum stress enhances the caffeine-induced apoptosis of hepatic stellate cells. <i>International Journal of Molecular Medicine</i> , 2017, 40, 1405-1414.	1.8	40
175	Risk and adverse outcomes of fractures in patients with liver cirrhosis: two nationwide retrospective cohort studies. <i>BMJ Open</i> , 2017, 7, e017342.	0.8	19
176	Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/ $\beta$ -Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. <i>EBioMedicine</i> , 2017, 23, 79-87.	2.7	76
177	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case–control study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1398-1406.	0.6	1
178	Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis. <i>Scientific Reports</i> , 2017, 7, 11482.	1.6	37
179	Metabolic characterization of hepatitis B virus-related liver cirrhosis using NMR-based serum metabolomics. <i>Metabolomics</i> , 2017, 13, 1.	1.4	10
180	The evaluation of non-invasive multi-slice spiral computed tomography-based indices for the diagnosis and prognosis prediction of liver cirrhosis. <i>Journal of Digestive Diseases</i> , 2017, 18, 472-479.	0.7	4
181	Hospital mortality in cirrhotic patients at a tertiary care center. <i>Revista De Gastroenterología De México (English Edition)</i> , 2017, 82, 203-209.	0.1	8
182	Human Muse Cells, Nontumorigenic Pluripotent-Like Stem Cells, Have Liver Regeneration Capacity through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis. <i>Cell Transplantation</i> , 2017, 26, 821-840.	1.2	69
183	Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. <i>Current Gastroenterology Reports</i> , 2017, 19, 45.	1.1	26
184	Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 317-325.	2.5	382
185	Administration of <i>Lactobacillus salivarius</i> LI01 or <i>Pediococcus pentosaceus</i> LI05 prevents CCl <sub>4</sub> -induced liver cirrhosis by protecting the intestinal barrier in rats. <i>Scientific Reports</i> , 2017, 7, 6927.	1.6	74

#	ARTICLE	IF	CITATIONS
186	Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection. <i>International Immunopharmacology</i> , 2017, 51, 1-8.	1.7	55
187	Prognostic impact and risk factors of low body mass index in patients undergoing liver transplantation. <i>Clinical Transplantation</i> , 2017, 31, e13048.	0.8	0
188	Risk factors associated with complications in cirrhotic patients undergoing endoscopic retrograde cholangio-pancreatography. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 238-243.	0.8	9
189	Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. <i>Journal of Hepatology</i> , 2017, 67, 1185-1193.	1.8	31
190	Rifaximin treatment for encephalopathy reduces hospital resource use: real-world data donâ€™t fail to IMPRESS. <i>Frontline Gastroenterology</i> , 2017, 8, 230-231.	0.9	2
194	Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	3.5	14
195	The spleen in liver cirrhosis: revisiting an old enemy with novel targets. <i>Journal of Translational Medicine</i> , 2017, 15, 111.	1.8	109
196	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	3.6	144
197	Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate. <i>Hepatology</i> , 2017, 65, 582-591.	3.6	52
198	Liver Surface Nodularity Score Allows Prediction of Cirrhosis Decompensation and Death. <i>Radiology</i> , 2017, 283, 711-722.	3.6	58
199	Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. <i>Liver International</i> , 2017, 37, 396-405.	1.9	113
200	Liver fibrosis staging with diffusion-weighted imaging: a systematic review and meta-analysis. <i>Abdominal Radiology</i> , 2017, 42, 490-501.	1.0	47
201	Surveillance liver MRI for monitoring patients with known or suspected chronic liver disease. <i>Clinical Radiology</i> , 2017, 72, 93.e7-93.e13.	0.5	4
202	Effects of portal vein thrombosis on the outcomes of liver cirrhosis: A Mexican perspective. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 189-191.	1.0	4
203	Occult liver disease burden: Analysis from a large general practitionersâ€™ database. <i>United European Gastroenterology Journal</i> , 2017, 5, 982-986.	1.6	12
204	Comparison of physical parameter measurements between peripheral and portal blood samples in patients with portal hypertension. <i>Technology and Health Care</i> , 2017, 25, 1147-1155.	0.5	0
205	<i>CXCL9</i> polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. <i>Clinical and Translational Medicine</i> , 2017, 6, 26.	1.7	13
206	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 297-318.	0.7	181

#	ARTICLE	IF	CITATIONS
207	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	1.4	38
208	Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 233-247.	0.6	34
209	Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. <i>Annals of Translational Medicine</i> , 2017, 5, 40-40.	0.7	67
210	Relative Adrenal Insufficiency is Associated with the Clinical Outcome in Patients with Stable Decompensated Cirrhosis. <i>Annals of Hepatology</i> , 2017, 16, 584-590.	0.6	11
211	Analysis of the effect of Qizhuyigan on liver function in a mouse model of immunological liver injury. <i>Tropical Journal of Pharmaceutical Research</i> , 2017, 16, 357.	0.2	1
212	Recurrent scrotal edema in liver cirrhosis. <i>AME Medical Journal</i> , 0, 2, 124-124.	0.4	0
213	Venous Thromboembolism in Liver Cirrhosis: An Emerging Issue. , 2017, , .		1
214	Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis. <i>AME Medical Journal</i> , 2017, , 39-39.	0.4	2
215	Is Human Cirrhosis a Reversible Disease?. , 2017, , 259-265.		1
217	How to Face Chronic Liver Disease: The Sinusoidal Perspective. <i>Frontiers in Medicine</i> , 2017, 4, 7.	1.2	36
218	miR-200c Accelerates Hepatic Stellate Cell-Induced Liver Fibrosis via Targeting the FOG2/PI3K Pathway. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	18
219	Evaluation of Adrenal Function in Nonhospitalized Patients with Cirrhosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-6.	0.8	14
220	Liver fibrosis: the 2017 state of art. <i>Panminerva Medica</i> , 2017, 59, 320-331.	0.2	53
221	Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis. <i>PLoS ONE</i> , 2017, 12, e0174142.	1.1	6
222	Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. <i>BMC Gastroenterology</i> , 2017, 17, 112.	0.8	37
223	Advances and challenges in cirrhosis and portal hypertension. <i>BMC Medicine</i> , 2017, 15, 200.	2.3	64
224	Castacin attenuates liver fibrosis and hepatic stellate cell activation by blocking TGF- $\beta$ <sup>2</sup> /Smad signaling pathway. <i>Oncotarget</i> , 2017, 8, 56267-56280.	0.8	44
225	Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1409-1414.	0.9	19

#	ARTICLE	IF	CITATIONS
226	[RETRACTED ARTICLE] Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e5234.	0.7	1
227	Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?. <i>Clinical and Experimental Hepatology</i> , 2017, 4, 181-186.	0.6	21
228	Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis. <i>International Journal of Medical Sciences</i> , 2017, 14, 240-245.	1.1	14
229	Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. <i>International Journal of Medical Sciences</i> , 2017, 14, 804-810.	1.1	1
230	Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study. <i>Annals of Hepatology</i> , 2017, 16, 123-132.	0.6	10
231	Ultrasonography for Noninvasive Assessment of Portal Hypertension. <i>Gut and Liver</i> , 2017, 11, 464-473.	1.4	36
232	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. <i>Radiology</i> , 2018, 286, 738-763.	3.6	215
233	Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. <i>Irish Journal of Medical Science</i> , 2018, 187, 925-934.	0.8	6
234	Closed-Loop Lumped Parameter Modeling of Hemodynamics During Cirrhogenesis in Rats. <i>IEEE Transactions on Biomedical Engineering</i> , 2018, 65, 2311-2322.	2.5	16
235	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1162-1169.	1.9	33
236	Liver cirrhosis and cancer: comparison of mortality. <i>Hepatology International</i> , 2018, 12, 269-276.	1.9	29
237	PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study. <i>Journal of Clinical Virology</i> , 2018, 103, 71-74.	1.6	10
239	Tissue Section Image-Based Liver Scar Detection. <i>Journal of Medical and Biological Engineering</i> , 2018, 38, 857-866.	1.0	6
240	Chronic Liver Failure and Hepatic Cirrhosis. , 2018, , 21-39.		1
241	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
242	Pre- vs. post-treatment with melatonin in CCl4-induced liver damage: Oxidative stress inferred from biochemical and pathohistological studies. <i>Life Sciences</i> , 2018, 202, 28-34.	2.0	18
243	Bioelectrical Impedance Analysisâ€œDerived Measurements in Chronic Hepatitis C: Clinical Relevance of Fatâ€œFree Mass and Phase Angle Evaluation. <i>Nutrition in Clinical Practice</i> , 2018, 33, 238-246.	1.1	17
244	Serum <i>Wisteria floribunda</i> agglutininâ€œpositive Macâ€œ2â€œbinding protein evaluates liver function and predicts prognosis in liver cirrhosis. <i>Journal of Digestive Diseases</i> , 2018, 19, 242-253.	0.7	7

#	ARTICLE	IF	CITATIONS
245	Editorial: macrophage activation markers predict prognosis and decompensation in patients with cirrhosis—linking gut permeability, inflammation and cirrhosis progression. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 851-853.	1.9	0
246	Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C—can one size fit all?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 853-854.	1.9	0
247	Fontan-associated Liver Disease. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 192-202.	0.4	12
248	Patient pathway: the ideal approach. <i>British Journal of Nursing</i> , 2018, 27, S14-S19.	0.3	0
249	Khat chewing increases the risk for developing chronic liver disease: A hospital-based case-control study. <i>Hepatology</i> , 2018, 68, 248-257.	3.6	21
250	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	1.9	31
251	Are we any closer to treating liver fibrosis (and if no, why not)?. <i>Journal of Digestive Diseases</i> , 2018, 19, 118-126.	0.7	9
252	Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 255-268.	2.9	43
253	Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?. <i>Digestive Diseases</i> , 2018, 36, 228-235.	0.8	2
255	Cuantificaci3n de la fibrosis hep3tica mediante biomarcadores de imagen. <i>Radiologia</i> , 2018, 60, 74-84.	0.3	8
256	Adeno-Associated Virus Serotype 2 Vector-Mediated Reintroduction of microRNA-19b Attenuates Hepatic Fibrosis. <i>Human Gene Therapy</i> , 2018, 29, 674-686.	1.4	21
257	Recent advances in three-dimensional cell culturing to assess liver function and dysfunction: from a drug biotransformation and toxicity perspective. <i>Toxicology Mechanisms and Methods</i> , 2018, 28, 369-385.	1.3	20
258	Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 243-251.	1.2	20
259	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314.	6.3	3,878
260	Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 329-336.	0.8	33
261	Precision analysis of a quantitative CT liver surface nodularity score. <i>Abdominal Radiology</i> , 2018, 43, 3307-3316.	1.0	15
263	Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites. <i>American Journal of Gastroenterology</i> , 2018, 113, 567-575.	0.2	7
264	Clinical Outcomes and Prognosis Markers of Patients With Liver Disease Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005727.	1.4	36



#	ARTICLE	IF	CITATIONS
265	Cost of illness of non-alcoholic liver cirrhosis in Japan: A time trend analysis and future projections. <i>Hepatology Research</i> , 2018, 48, 176-183.	1.8	8
266	Invasive and non-invasive assessment of portal hypertension. <i>Hepatology International</i> , 2018, 12, 44-55.	1.9	42
267	Epigenetic Effects of an Adenosine Derivative in a Wistar Rat Model of Liver Cirrhosis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 401-413.	1.2	14
268	M2BPG as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	12
269	Disrupted topological organization of brain structural network associated with prior overt hepatic encephalopathy in cirrhotic patients. <i>European Radiology</i> , 2018, 28, 85-95.	2.3	7
270	Impact of etiological treatment on prognosis. <i>Hepatology International</i> , 2018, 12, 56-67.	1.9	12
271	Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies. <i>Hepatology</i> , 2018, 67, 1458-1471.	3.6	44
272	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	1.9	28
273	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1146-1152.e4.	2.4	77
274	Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. <i>Digestive and Liver Disease</i> , 2018, 50, 54-60.	0.4	50
275	Transjugular intrahepatic portosystemic shunt as a bridge to non-hepatic surgery in cirrhotic patients with severe portal hypertension: a systematic review. <i>Hpb</i> , 2018, 20, 101-109.	0.1	28
276	The portal hypertension syndrome: etiology, classification, relevance, and animal models. <i>Hepatology International</i> , 2018, 12, 1-10.	1.9	81
277	Clinical states of cirrhosis and competing risks. <i>Journal of Hepatology</i> , 2018, 68, 563-576.	1.8	302
278	Inflammation is regulated by the adenosine derivative molecule, IFC-305, during reversion of cirrhosis in a CCl4 rat model. <i>International Immunopharmacology</i> , 2018, 54, 12-23.	1.7	15
279	T2*-weighted imaging of the liver versus the spleen to assess hepatitis B-related cirrhosis and its Child-Pugh class. <i>Radiology of Infectious Diseases</i> , 2018, 5, 33-40.	2.4	0
280	Elastography methods for the non-invasive assessment of portal hypertension. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 155-164.	1.4	54
281	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018, 38, 636-644.	1.9	34
282	Exercise might prevent cirrhosis in overweight and obese adults. <i>Liver International</i> , 2018, 38, 515-522.	1.9	2



#	ARTICLE	IF	CITATIONS
283	Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. <i>Journal of Gastroenterology</i> , 2018, 53, 652-659.	2.3	16
284	Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. <i>Hepatology</i> , 2018, 67, 2141-2149.	3.6	178
285	Comparison of gradient-recalled echo and spin-echo echo-planar imaging MR elastography in staging liver fibrosis: a meta-analysis. <i>European Radiology</i> , 2018, 28, 1709-1718.	2.3	49
286	Repetitive restraint stress changes spleen immune cell subsets through glucocorticoid receptor or $\beta^2$ -adrenergic receptor in a stage dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 1108-1114.	1.0	36
287	Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 709-720.	1.8	34
288	Cirrhosis and LI-RADS. <i>Abdominal Radiology</i> , 2018, 43, 26-40.	1.0	12
289	Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 207-211.	0.8	26
290	Pharmacologic prevention of variceal bleeding and rebleeding. <i>Hepatology International</i> , 2018, 12, 68-80.	1.9	36
291	Quantitative analysis of hepatic macro- and microvascular alterations during cirrhogenesis in the rat. <i>Journal of Anatomy</i> , 2018, 232, 485-496.	0.9	17
292	A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 942-951.	2.8	19
293	Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice. <i>Hepatology</i> , 2018, 67, 296-312.	3.6	76
294	Fontan-Associated Liver Disease: A Review. <i>Annals of Hepatology</i> , 2018, 17, 192-204.	0.6	65
295	New Insights About Albumin and Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 547-560.	0.6	125
296	Nursing clinical competence in area medica. <i>Italian Journal of Medicine</i> , 2018, , 1-83.	0.2	0
297	The use of statins in the management of chronic liver disease. <i>AME Medical Journal</i> , 2018, 3, 3-3.	0.4	1
298	WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 343-345.	0.3	2
299	Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e13302.	0.4	4
300	UEG Week 2018 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2018, 6, A135.	1.6	27

#	ARTICLE	IF	CITATIONS
301	<i>A Sargassum fluitans</i> Borgesen Ethanol Extract Exhibits a Hepatoprotective Effect In Vivo in Acute and Chronic Liver Damage Models. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	11
302	Portal Vein Thrombosis in Liver Cirrhosis. , 2018, , .		0
303	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	19
304	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	2
305	Primary prevention of bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	3
306	Secondary prevention of bleeding in people with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	1
307	Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	1
308	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	1
309	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	2
310	Favorable clinical outcome of nonalcoholic liver cirrhosis patients with coronary artery disease: A population-based study. <i>World Journal of Gastroenterology</i> , 2018, 24, 3547-3555.	1.4	6
311	Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 453-461.	0.7	63
312	Validation of a Symptoms Distress Scale in a Cirrhotic Population Using Item Response Theory. <i>Nursing Research</i> , 2018, 67, 359-368.	0.8	0
313	Macrocytic anemia is associated with the severity of liver impairment in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective cross-sectional study. <i>BMC Gastroenterology</i> , 2018, 18, 161.	0.8	17
314	Mnemonic to Assist in Management of Liver Cirrhosis. <i>Journal for Nurse Practitioners</i> , 2018, 14, 732-738.	0.4	8
315	Dietary management and supplementation with branched-chain amino acids in cirrhosis of the liver. <i>Revista De GastroenterologAa De MÃ©xico (English Edition)</i> , 2018, 83, 424-433.	0.1	0
316	Doxazosin and Carvedilol Treatment Improves Hepatic Regeneration in a Hamster Model of Cirrhosis. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	13
317	Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study. <i>Frontiers in Microbiology</i> , 2018, 9, 3166.	1.5	57
318	Small Esophageal Varices in Patients with Cirrhosisâ€”Should We Treat Them?. <i>Current Hepatology Reports</i> , 2018, 17, 301-315.	0.4	17

#	ARTICLE	IF	CITATIONS
319	Pneumonia in patients with cirrhosis: risk factors associated with mortality and predictive value of prognostic models. <i>Respiratory Research</i> , 2018, 19, 242.	1.4	21
320	The Myeloid-Epithelial-Reproductive Tyrosine Kinase (MERTK) rs4374383 Polymorphism Predicts Progression of Liver Fibrosis in Hepatitis C Virus-Infected Patients: A Longitudinal Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 473.	1.0	15
321	The Benefits of Neuromuscular Electrical Stimulation in the Muscular and Functional Capacity of Patients With Liver Cirrhosis: Protocol for a Randomized Clinical Trial. <i>Clinical Medicine Insights Gastroenterology</i> , 2018, 11, 117955221881183.	1.0	0
322	Manejo dietético y suplementación con aminoácidos de cadena ramificada en cirrosis hepática. <i>Revista De Gastroenterología De México</i> , 2018, 83, 424-433.	0.4	11
323	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	0.7	11
324	Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1107-1113.	0.6	18
325	Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. <i>EBioMedicine</i> , 2018, 36, 151-158.	2.7	64
326	Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 611-621.	0.9	31
327	Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). <i>United European Gastroenterology Journal</i> , 2018, 6, 1380-1390.	1.6	24
328	Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1153-1164.	0.6	26
329	Electrochemical Molecular Switch for the Selective Profiling of Cysteine in Live Cells and Whole Blood and for the Quantification of Aminoacylase-1. <i>Analytical Chemistry</i> , 2018, 90, 12631-12638.	3.2	32
330	Primary rat LSECs preserve their characteristic phenotype after cryopreservation. <i>Scientific Reports</i> , 2018, 8, 14657.	1.6	9
331	Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2018, 155, 1564-1577.	0.6	97
332	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	1.6	27
333	Chinese herbal medicine therapy and the risk of mortality for chronic hepatitis B patients with concurrent liver cirrhosis: a nationwide population-based cohort study. <i>Oncotarget</i> , 2018, 9, 18214-18223.	0.8	10
334	Clinical impact of microbiome in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3813-3820.	1.4	27
335	Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 87-93.	0.9	9
336	Thymosin $\alpha_4$ Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	1.9	44

#	ARTICLE	IF	CITATIONS
337	Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e154.	1.3	14
338	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. <i>Radiology</i> , 2018, 289, 698-707.	3.6	45
339	The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. <i>PLoS ONE</i> , 2018, 13, e0197115.	1.1	10
340	Efficacy and safety of autologous stem cell transplantation for decompensated liver cirrhosis: A retrospective cohort study. <i>World Journal of Stem Cells</i> , 2018, 10, 138-145.	1.3	7
341	CXCL10-induced IL-9 promotes liver fibrosis via Raf/MEK/ERK signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 282-289.	2.5	26
342	Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. <i>European Radiology</i> , 2018, 28, 5221-5230.	2.3	20
343	Hepatic Venous Pressure Measurement and Other Diagnostic Hepatic Hemodynamic Techniques. , 2018, , 33-48.		0
344	Long-term Changes in Spleen Volume After Living Donor Liver Transplantation in Pediatric Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 2723-2725.	0.3	1
345	MicroRNA-125b Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Activating RhoA Signaling. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 57-66.	2.3	43
346	MicroRNA profiles in serum samples from patients with stable cirrhosis and miRNA-21 as a predictor of transplant-free survival. <i>Pharmacological Research</i> , 2018, 134, 179-192.	3.1	19
347	A New Intelligent Medical Decision Support System Based on Enhanced Hierarchical Clustering and Random Decision Forest for the Classification of Alcoholic Liver Damage, Primary Hepatoma, Liver Cirrhosis, and Cholelithiasis. <i>Journal of Healthcare Engineering</i> , 2018, 2018, 1-9.	1.1	14
348	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	5
349	Clinical Assessment and Management of Portal Hypertension. <i>Seminars in Interventional Radiology</i> , 2018, 35, 153-159.	0.3	11
350	Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 963.	1.5	38
351	Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1317-1325.	0.9	9
352	Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF- $\kappa$ B/iNOS signaling pathway. <i>Food and Chemical Toxicology</i> , 2018, 120, 294-304.	1.8	46
353	Unique subgingival microbiota associated with periodontitis in cirrhosis patients. <i>Scientific Reports</i> , 2018, 8, 10718.	1.6	27
354	Periodontal status of liver transplant candidates and healthy controls. <i>Journal of Periodontology</i> , 2018, 89, 1383-1389.	1.7	14

#	ARTICLE	IF	CITATIONS
355	Cut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. <i>Visceral Medicine</i> , 2018, 34, 270-275.	0.5	39
356	Unexplained chronic liver disease in Ethiopia: a cross-sectional study. <i>BMC Gastroenterology</i> , 2018, 18, 27.	0.8	25
357	Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. <i>Hepatology</i> , 2018, 68, 1308-1318.	3.6	113
358	Association between sarcopenia and osteoporosis in chronic liver disease. <i>Hepatology Research</i> , 2018, 48, 893-904.	1.8	33
359	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	1.3	22
360	External validation and improvement of LiFe score as a prediction tool in critically ill cirrhosis patients. <i>Hepatology Research</i> , 2018, 48, 905-913.	1.8	7
361	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.4	7
362	Bletilla striata polysaccharide has a protective effect on intestinal epithelial barrier disruption in TAA-induced cirrhotic rats. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 1715-1722.	0.8	11
363	Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices. <i>Journal of Clinical Ultrasound</i> , 2018, 46, 442-449.	0.4	31
364	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	1.8	152
365	Stem/Progenitor Cells in Chronically Injured Liver and the Surrounding Microenvironment. , 2018, , 255-272.		0
366	Risk of seizures and status epilepticus in older patients with liver disease. <i>Epilepsia</i> , 2018, 59, 1392-1397.	2.6	4
367	Liver disease. , 2018, , 425-432.		0
368	Dual-energy computed tomography for noninvasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data. <i>Hepatology Research</i> , 2018, 48, 1008-1019.	1.8	45
369	Animal models of portal hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1019-1030.	1.8	22
370	A comparative study of subsequent liver cirrhosis risk in non-Helicobacter pylori-infected peptic ulcer patients with and without vagotomy: An Asian population cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 376-382.	1.4	3
371	Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. <i>Gut</i> , 2019, 68, 844-853.	6.1	77
372	HCV treatment with direct acting antivirals improves the insulin sensitivity. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 749-754.	2.0	13

#	ARTICLE	IF	CITATIONS
373	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. <i>JHEP Reports</i> , 2019, 1, 270-277.	2.6	12
374	Red cell distribution width to platelet ratio for liver fibrosis: a systematic review and meta-analysis of diagnostic accuracy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 877-891.	1.4	11
375	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. <i>FASEB Journal</i> , 2019, 33, 11595-11605.	0.2	68
376	Derivation and external validation of a model to predict 2-year mortality risk of patients with advanced schistosomiasis after discharge. <i>EBioMedicine</i> , 2019, 47, 309-318.	2.7	17
377	Insulin resistance is not a risk factor for oesophageal varices development in hepatitis C. <i>Tropical Doctor</i> , 2019, 49, 281-285.	0.2	2
378	AST to platelet ratio index for predicting the in hospital mortality in chronic liver disease patients in tertiary care hospital. <i>Asian Journal of Medical Sciences</i> , 2019, 10, 44-48.	0.0	0
379	RIP3 deficiency alleviates liver fibrosis by inhibiting ROCK1â€“TLR4â€“NFâ€“B pathway in macrophages. <i>FASEB Journal</i> , 2019, 33, 11180-11193.	0.2	31
380	Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity. <i>Heliyon</i> , 2019, 5, e02114.	1.4	6
381	Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 308-329.	1.4	55
382	Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis. <i>PeerJ</i> , 2019, 7, e6645.	0.9	31
383	Revision of meso-Rex bypass utilizing a collateral vein in a patient with portal steal phenomenon after liver transplant: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 60, 230-233.	0.2	3
384	Kaempferol attenuates liver fibrosis by inhibiting activin receptorâ€“like kinase 5. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6403-6410.	1.6	39
385	Value of radiomic analysis of data from magnetic resonance elastography for diagnosing fibrosis stages in patients with hepatitis B/C. <i>Chinese Journal of Academic Radiology</i> , 2019, 1, 74-84.	0.4	3
386	Liver transplantation in Mexican older adults: A comparative single-center study. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2019, 84, 455-460.	0.1	0
387	Metabolism in Acute-On-Chronic Liver Failure: The Solution Moreâ€“thanâ€“theâ€“Problem. <i>Archives of Medical Research</i> , 2019, 50, 271-284.	1.5	1
388	Molecular prognosis in liver cirrhosis. , 2019, , 413-427.		0
389	Muscle psoas indices measured by ultrasound in cirrhosis â€” Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. <i>Digestive and Liver Disease</i> , 2019, 51, 1502-1507.	0.4	27
390	Liver shape analysis using partial least squares regression-based statistical shape model: application for understanding and staging of liver fibrosis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2019, 14, 2083-2093.	1.7	10

#	ARTICLE	IF	CITATIONS
391	Sequential drug delivery for liver diseases. <i>Advanced Drug Delivery Reviews</i> , 2019, 149-150, 72-84.	6.6	7
392	Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. <i>CMAJ Open</i> , 2019, 7, E610-E617.	1.1	22
393	Planar metamaterial analogue of electromagnetically induced transparency for a miniature refractive index sensor. <i>Physics Letters, Section A: General, Atomic and Solid State Physics</i> , 2019, 383, 125947.	0.9	21
394	Portal hypertension in non-alcoholic fatty liver disease. <i>Gastrointestinal Nursing</i> , 2019, 17, 16-18.	0.0	0
395	LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis. <i>Cell</i> , 2019, 178, 1478-1492.e20.	13.5	122
397	Hyperactive Follicular Helper T Cells Contribute to Dysregulated Humoral Immunity in Patients With Liver Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 1915.	2.2	15
398	A novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis. <i>Journal of Translational Medicine</i> , 2019, 17, 280.	1.8	19
399	Ageing Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
400	Phenotypical and Functional Polymorphism of Liver Resident Macrophages. <i>Cells</i> , 2019, 8, 1032.	1.8	47
401	The miRFIB-Score: A Serological miRNA-Based Scoring Algorithm for the Diagnosis of Significant Liver Fibrosis. <i>Cells</i> , 2019, 8, 1003.	1.8	19
402	Serum Ferritin Levels: A Potential Biomarker to Represent Child-Turcotte-Pugh Score among Decompensated Liver Cirrhosis Patients. <i>The Malaysian Journal of Medical Sciences</i> , 2019, 26, 59-65.	0.3	2
403	Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 378-387.	1.4	16
404	Trasplante de h�gado en adultos mayores mexicanos: un estudio comparativo en un solo centro. <i>Revista De Gastroenterolog�a De M�xico</i> , 2019, 84, 455-460.	0.4	0
405	Molecular and Cellular Aspects of Cirrhosis and How an Adenosine Derivative Could Revert Fibrosis. , 0, , .		3
406	Enzymatic liver function measured by LiMAx � a reliable diagnostic and prognostic tool in chronic liver disease. <i>Scientific Reports</i> , 2019, 9, 13577.	1.6	12
407	Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults. <i>Scientific Reports</i> , 2019, 9, 785.	1.6	21
408	A new algorithm for predicting long-term survival in chronic hepatitis B patients with variceal bleeding after endoscopic therapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1166-1171.	0.4	3
409	Determination of the predictive factors for significant liver fibrosis assessed through transient elastography. <i>Advances in Digestive Medicine</i> , 2019, 6, 5-14.	0.1	2



#	ARTICLE	IF	CITATIONS
410	Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 4568-4576.	0.8	7
411	ALBI and PALBI Grades Are Associated with the Outcome of Patients with Stable Decompensated Cirrhosis. <i>Annals of Hepatology</i> , 2019, 18, 126-136.	0.6	32
412	Value of whole-liver apparent diffusion coefficient histogram analysis for quantification of liver fibrosis stages. <i>Chinese Journal of Academic Radiology</i> , 2019, 1, 6-12.	0.4	0
413	Improvement of energy substrate metabolism by late evening snack supplementation in patients with liver cirrhosis: a meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 659-668.	0.9	5
414	Current and future pharmacological therapies for managing cirrhosis and its complications. <i>World Journal of Gastroenterology</i> , 2019, 25, 888-908.	1.4	36
415	Potential circulating biomarkers of circulating chemokines CCL5, MIP-1 $\beta$ and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection. <i>BMC Infectious Diseases</i> , 2019, 19, 523.	1.3	12
416	Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 1692-1697.	0.4	7
417	Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy. <i>BMC Gastroenterology</i> , 2019, 19, 101.	0.8	6
418	MANF regulates splenic macrophage differentiation in mice. <i>Immunology Letters</i> , 2019, 212, 37-45.	1.1	21
419	Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. <i>Liver International</i> , 2019, 39, 1557-1565.	1.9	18
420	Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. <i>Hepatology Communications</i> , 2019, 3, 987-1000.	2.0	37
421	Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 782.	1.0	12
422	CircMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5486-5496.	1.6	50
423	Association Between Institutional Factors and Long-Term Survival Following Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , 2019, 3, 838-846.	2.0	6
424	Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 955-965.	1.7	9
425	Beneficial impact of microwave ablation-assisted laparoscopic hepatectomy in cirrhotic hepatocellular carcinoma patients: a propensity score matching analysis. <i>International Journal of Hyperthermia</i> , 2019, 36, 529-536.	1.1	2
426	Acute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit. <i>JHEP Reports</i> , 2019, 1, 44-52.	2.6	22
427	Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K/AKT and cGMP signalling pathways. <i>Scientific Reports</i> , 2019, 9, 6993.	1.6	6



#	ARTICLE	IF	CITATIONS
428	Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B or C by Contrast-Enhanced Magnetic Resonance Imaging. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-8.	0.8	9
429	Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials. <i>Stem Cells International</i> , 2019, 2019, 1-12.	1.2	45
430	Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 16-23.	0.8	14
431	Flash Imaging Used in the Post-vascular Phase of Contrast-Enhanced Ultrasonography is Useful for Assessing the Progression in Patients with Hepatitis C Virus-Related Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1654-1662.	0.7	7
433	Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2653-2660.	1.1	33
434	Metabolic mechanisms of Fuzheng-Huayu formula against liver fibrosis in rats. <i>Journal of Ethnopharmacology</i> , 2019, 238, 111888.	2.0	15
435	Blood-Brain Barrier: Morphology, Regulation, and Pathophysiology. <i>Gene Expression</i> , 2019, 19, 69-87.	0.5	32
436	Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-9.	1.4	40
437	TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1277.	1.8	37
438	Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1432-1440.	1.4	18
439	Original Study: Transjugular Intrahepatic Portosystemic Shunt as a Bridge to Abdominal Surgery in Cirrhotic Patients. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2383-2390.	0.9	32
440	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	6.3	375
441	Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. <i>Biomolecules</i> , 2019, 9, 143.	1.8	7
442	Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. <i>Seminars in Liver Disease</i> , 2019, 39, 249-260.	1.8	45
443	Senescent Hepatocytes in Decompensated Liver Show Reduced UPRMT and Its Key Player, CLPP, Attenuates Senescence In Vitro. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 73-94.	2.3	24
444	Association Between Renal Function Pattern and Mortality in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2364-2370.	2.4	37
445	Assessment of liver cirrhosis for patients with Child's A classification before hepatectomy using dynamic contrast-enhanced MRI. <i>Clinical Radiology</i> , 2019, 74, 407.e11-407.e17.	0.5	7
446	The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C. <i>Quality of Life Research</i> , 2019, 28, 1531-1542.	1.5	8

#	ARTICLE	IF	CITATIONS
447	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. <i>Radiologic Clinics of North America</i> , 2019, 57, 563-583.	0.9	7
448	Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	1.9	42
449	The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 827-839.	1.1	9
450	Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics (HVPG<sub>BFM</sub>): protocol for a prospective, randomised, non-controlled, multicentre study. <i>BMJ Open</i> , 2019, 9, e028518.	0.8	4
451	Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). <i>BMJ Open Gastroenterology</i> , 2019, 6, e000316.	1.1	8
452	External validation of Liaoning score for predicting esophageal varices in liver cirrhosis: a Chinese multicenter cross-sectional study. <i>Annals of Translational Medicine</i> , 2019, 7, 755-755.	0.7	11
453	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2019, 9, CD013120.	1.5	7
454	Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology. <i>Cells</i> , 2019, 8, 1423.	1.8	54
455	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2019, 2019, CD013103.	1.5	35
456	Serum lipopolysaccharides predict advanced liver disease in the general population. <i>JHEP Reports</i> , 2019, 1, 345-352.	2.6	27
457	Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2019, 19, 231.	0.8	32
458	Incidence and hemodynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. <i>International Journal of Medical Sciences</i> , 2019, 16, 1614-1620.	1.1	10
459	Autologous stem cell transplantation for patients with viral hepatitis-induced liver cirrhosis: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1283-1291.	0.8	8
460	Telbivudine on IgG-associated hypergammaglobulinemia and TGF- $\beta$ 1 hyperactivity in hepatitis B virus-related liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0225482.	1.1	2
461	Fibrosis and the intestinal microbiome; a focus on chronic liver disease. <i>Current Opinion in Pharmacology</i> , 2019, 49, 76-81.	1.7	12
462	The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1169-1180.	1.4	19
463	Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 2057.	1.0	10
464	Plasma D-dimer as a novel biomarker for predicting poor outcomes in HBV-related decompensated cirrhosis. <i>Medicine (United States)</i> , 2019, 98, e18527.	0.4	9

#	ARTICLE	IF	CITATIONS
465	Sarcopenia impairs health-related quality of life in cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1550-1556.	0.8	21
466	Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. <i>Medicine (United States)</i> , 2019, 98, e18366.	0.4	4
467	Serum CD64 and ascitic fluid calprotectin and microRNA-155 as potential biomarkers of spontaneous bacterial peritonitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1064-1069.	0.8	15
468	Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	20
469	Identifying characteristics of drug-related problems in critically ill patients with decompensated liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1569-1576.	0.8	6
470	Renal impairment is associated with increased risk of mortality in patients with cirrhosis. <i>Medicine (United States)</i> , 2019, 98, e14475.	0.4	9
471	Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. <i>Medicine (United States)</i> , 2019, 98, e18020.	0.4	3
472	Contrast-Enhanced CT May Be a Diagnostic Alternative for Gastroesophageal Varices in Cirrhosis with and without Previous Endoscopic Variceal Therapy. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-15.	0.7	9
473	Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1574-1586.	0.2	172
474	Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 236-241.	1.1	6
475	Therapeutic Effect of Tanshinone IIA on Liver Fibrosis and the Possible Mechanism: A Preclinical Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-13.	0.5	12
476	Mechanisms of Huangqi Decoction Granules (è»„,èŠª±éŒ—ç²’â%„) on Hepatitis B Cirrhosis Patients Based on RNA-Sequencing. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 507-514.	0.7	10
477	Interleukin-10 promoter gene polymorphisms are associated with the first major depressive episode in chronic hepatitis C patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 417-426.	0.7	3
478	Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. <i>Journal of Hepatology</i> , 2019, 70, 722-734.	1.8	38
479	Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An ageâ€periodâ€cohort analysis. <i>Liver International</i> , 2019, 39, 770-776.	1.9	11
480	Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). <i>Digestive Diseases and Sciences</i> , 2019, 64, 1335-1345.	1.1	50
481	Thrombocytopenia: A prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1214-1221.	1.4	8
482	Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. <i>Radiology</i> , 2019, 290, 370-377.	3.6	43

#	ARTICLE	IF	CITATIONS
483	A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. <i>Infectious Diseases and Therapy</i> , 2019, 8, 33-50.	1.8	50
484	<i>Principles of Clinical Epidemiology.</i> , 2019, , 1-15.		1
485	Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF- $\beta$ 1/Smad and NOX4/ROS pathways. <i>Chemico-Biological Interactions</i> , 2019, 299, 131-139.	1.7	87
486	Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients. <i>Nutrition Research</i> , 2019, 61, 82-94.	1.3	16
487	Portal hypertension: The desperate search for the placenta. <i>Current Research in Translational Medicine</i> , 2019, 67, 56-61.	1.2	0
488	Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study. <i>Academic Radiology</i> , 2019, 26, 872-877.	1.3	13
489	Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 234-241.	0.6	20
491	Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis. <i>Radiologia Medica</i> , 2020, 125, 7-14.	4.7	33
492	Splenic serum from portal hypertensive patients enhances liver stem cell proliferation and self-renewal via the IGF-II/ERK signaling pathway. <i>Digestive and Liver Disease</i> , 2020, 52, 205-213.	0.4	1
493	MRI cine- $\epsilon$ tagging of cardiac-induced motion for noninvasive staging of liver fibrosis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1570-1580.	1.9	6
494	Decellularized liver matrix as substrates for rescue of acute hepatocytes toxicity. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2020, 108, 1592-1602.	1.6	15
495	Two-dimensional Shear Wave Elastography with Propagation Maps for the Assessment of Liver Fibrosis and Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Prospective Study. <i>Academic Radiology</i> , 2020, 27, 798-806.	1.3	12
496	Dual-frequency MR elastography to differentiate between inflammation and fibrosis of the liver: Comparison with histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1053-1064.	1.9	6
497	Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation. <i>Autophagy</i> , 2020, 16, 782-796.	4.3	80
498	Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. <i>Hepatology</i> , 2020, 71, 627-642.	3.6	32
499	Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. <i>European Radiology</i> , 2020, 30, 1264-1273.	2.3	77
500	Liquiritigenin suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis. <i>Phytomedicine</i> , 2020, 66, 153108.	2.3	16
501	Cytochrome P450-derived eicosanoids and inflammation in liver diseases. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 147, 106400.	1.0	26

#	ARTICLE	IF	CITATIONS
502	Atrial fibrillation in hospitalized patients with end-stage liver disease: temporal trends in prevalence and outcomes. <i>Liver International</i> , 2020, 40, 674-684.	1.9	6
503	Withdrawal. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 554-554.	1.2	1
504	Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the <i>EGFR-FAK-AKT/ERK1/2-Slug</i> Signaling Pathway in Human Hepatocellular Carcinoma. <i>DNA and Cell Biology</i> , 2020, 39, 355-367.	0.9	13
505	Beta-blockers in cirrhosis: Evidence-based indications and limitations. <i>JHEP Reports</i> , 2020, 2, 100063.	2.6	81
506	Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. <i>Platelets</i> , 2020, 31, 1019-1027.	1.1	5
507	Anesthesia for the Patient with Severe Liver Failure. <i>Anesthesiology Clinics</i> , 2020, 38, 35-50.	0.6	5
508	Survival of endogenous hepatic stem/progenitor cells in liver tissues during liver cirrhosis. <i>Life Sciences</i> , 2020, 241, 117121.	2.0	15
509	Assessment of Written Patient Information Pertaining to Cirrhosis and Its Complications: A Pilot Study. <i>Journal of Patient Experience</i> , 2020, 7, 499-506.	0.4	5
510	Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 45-57.	1.5	24
511	Cirrhosis, Thrombosis, Finding FaXts about Doses: Dosing of Unfractionated Heparin for Venous Thromboembolism in Cirrhosis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 450-456.	0.9	1
512	Combined liver and islet transplantation in hepatogenous diabetes, cluster exenteration, and cirrhosis with type 1 diabetes. , 2020, , 439-453.		1
513	Effect of liver disease on post-therapeutic complications of head and neck squamous cell carcinoma. A prospective study of 94 patients. <i>Clinical Otolaryngology</i> , 2020, 45, 292-296.	0.6	1
514	Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. <i>Frontiers in Oncology</i> , 2020, 10, 1759.	1.3	9
515	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18
516	Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. <i>Journal of Evidence-Based Medicine</i> , 2020, 13, 313-324.	0.7	14
517	Pinostilbene hydrate suppresses hepatic stellate cell activation via inhibition of miR-17-5p-mediated Wnt/ $\beta$ -catenin pathway. <i>Phytomedicine</i> , 2020, 79, 153321.	2.3	11
518	A cohort study on long-term exposure to air pollution and incidence of liver cirrhosis. <i>Environmental Epidemiology</i> , 2020, 4, e109.	1.4	17
519	Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis. <i>Medicine (United States)</i> , 2020, 99, e22065.	0.4	2

#	ARTICLE	IF	CITATIONS
520	Cirrosis hepática. <i>Medicine</i> , 2020, 13, 297-307.	0.0	2
521	Hipertensión portal. <i>Medicine</i> , 2020, 13, 308-315.	0.0	2
522	Transjugular intrahepatic portosystemic shunt for repeated bleeding of hemorrhoids caused by severe portal hypertension with ectopic varices: A case report. <i>Journal of Interventional Medicine</i> , 2020, 3, 157-160.	0.2	0
523	Preoperative Evaluation and Anesthetic Management of Patients With Liver Cirrhosis Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, , .	0.6	4
524	Mean Platelet Volume/Lymphocyte Ratio as a Prognostic Indicator for HBV-Related Decompensated Cirrhosis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	7
525	Early rebleeding increases mortality of variceal bleeders on secondary prophylaxis with $\beta$ -blockers and ligation. <i>Digestive and Liver Disease</i> , 2020, 52, 1017-1025.	0.4	11
526	Intensive care utilization in patients with end-stage liver disease: A population-based comparative study of cohorts with and without comorbid hepatocellular carcinoma in Taiwan. <i>EClinicalMedicine</i> , 2020, 22, 100357.	3.2	0
527	Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. , 2020, 215, 107626.		13
528	Evaluation of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and red cell distribution width for the prediction of prognosis of patients with hepatitis B virus-related decompensated cirrhosis. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23478.	0.9	13
529	Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102267.	1.7	12
530	Pituitary adenylate cyclase-activating peptide: Potential roles in the pathophysiology and complications of cirrhosis. <i>Liver International</i> , 2020, 40, 2578-2589.	1.9	2
531	Role of B Cell Lymphoma 2 in the Regulation of Liver Fibrosis in miR-122 Knockout Mice. <i>Biology</i> , 2020, 9, 157.	1.3	7
532	Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. <i>Cancers</i> , 2020, 12, 1805.	1.7	23
533	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , 2020, 72, 1378-1393.	3.6	29
534	Cellular Location of HNF4 $\alpha$ is Linked With Terminal Liver Failure in Humans. <i>Hepatology Communications</i> , 2020, 4, 859-875.	2.0	12
535	Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3343-3351.	1.1	0
536	When demand exceeds supply: Liver transplantation due to alcohol use disorder in Austria. <i>Neuropsychiatrie</i> , 2020, 34, 157-163.	1.3	2
537	Multimodal Ultrasound Model Based on the Left Gastric Vein in B-Viral Cirrhosis: Noninvasive Prediction of Esophageal Varices. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00262.	1.3	5



#	ARTICLE	IF	CITATIONS
538	Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization. <i>Biomolecules</i> , 2020, 10, 1585.	1.8	33
539	Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 2488.	1.0	28
540	Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia. <i>International Journal of Medical Sciences</i> , 2020, 17, 1345-1350.	1.1	7
541	Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis. <i>PLoS ONE</i> , 2020, 15, e0236528.	1.1	4
542	RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153147.	1.0	1
543	LEFTY2 alleviates hepatic stellate cell activation and liver fibrosis by regulating the TGF- $\beta$ 1/Smad3 pathway. <i>Molecular Immunology</i> , 2020, 126, 31-39.	1.0	18
544	Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1760.	2.2	2
545	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1042-1050.	1.9	7
546	Anesthesia for the Patient with Severe Liver Failure. <i>Advances in Anesthesia</i> , 2020, 38, 251-267.	0.5	1
547	Metabolic defects in splenic B cell compartments from patients with liver cirrhosis. <i>Cell Death and Disease</i> , 2020, 11, 915.	2.7	3
548	Platelet-to-white blood cell ratio: A novel and promising prognostic marker for HBV-associated decompensated cirrhosis. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23556.	0.9	11
549	Preoperative Inversed Albumin-to-Globulin Ratio Predicts Worse Oncologic Prognosis Following Curative Hepatectomy for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 9929-9939.	0.9	10
550	Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. <i>Nutrients</i> , 2020, 12, 2627.	1.7	14
551	Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6223.	1.8	9
552	Study of alcoholic chronic pancreatitis and alcoholic liver cirrhosis could be improved. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1406-1407.	0.8	0
553	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound Toward Improved Detection of Liver Impairment. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00239.	1.3	34
554	Assessment of a biofluid mechanics-based model for calculating portal pressure in canines. <i>BMC Veterinary Research</i> , 2020, 16, 308.	0.7	0
555	Kupffer Cells. <i>American Journal of Pathology</i> , 2020, 190, 2185-2193.	1.9	80

#	ARTICLE	IF	CITATIONS
556	Early Multiplexed Detection of Cirrhosis using Giant Magnetoresistive Biosensors with Protein Biomarkers. <i>ACS Sensors</i> , 2020, 5, 3049-3057.	4.0	15
557	Kupffer Cell-Derived TNF- $\alpha$ Triggers the Apoptosis of Hepatic Stellate Cells through TNF-R1/Caspase 8 due to ER Stress. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	2
558	Assessment of native liver fibrosis using ultrasound elastography and serological fibrosis indices in children with biliary atresia after the Kasai procedure. <i>Acta Radiologica</i> , 2021, 62, 1088-1096.	0.5	19
559	Association of physical activity with risk of hepatobiliary diseases in China: a prospective cohort study of 0.5 million people. <i>British Journal of Sports Medicine</i> , 2021, 55, 1024-1033.	3.1	19
560	Thrombin Generation and Cirrhosis: State of the Art and Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 693-703.	1.5	33
561	Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-10.	0.7	4
562	Aging and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2020, 40, 373-384.	1.8	21
563	Acupuncture for the Treatment of Liver Cirrhosis: A Meta-analysis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-9.	0.7	3
564	Alternation of supragingival microbiome in patients with cirrhosis of different Child-Pugh scores. <i>Oral Diseases</i> , 2022, 28, 233-242.	1.5	1
565	Comparing Mortality Risk Predictive Ability of Different Scoring Systems in Cirrhotic Patients with Bacteremia. <i>Emergency Medicine International</i> , 2020, 2020, 1-6.	0.3	1
566	Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 153-172.	0.9	15
567	Observational and Genetic Associations of Body Mass Index and Hepatobiliary Diseases in a Relatively Lean Chinese Population. <i>JAMA Network Open</i> , 2020, 3, e2018721.	2.8	11
568	Nursing Management of Hepatic Encephalopathy. <i>Gastroenterology Nursing</i> , 2020, 43, E35-E47.	0.2	4
569	Noninvasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	1.9	14
570	The Perfect Sleeve Gastrectomy. , 2020, , .		6
571	Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis. <i>Journal of Translational Medicine</i> , 2020, 18, 187.	1.8	7
572	Diagnostic Performance of Ultrasound Elastography and Serologic Fibrosis Indices for Evaluation of Hepatic Involvement in Wilson Disease. <i>Journal of Ultrasound in Medicine</i> , 2020, 39, 2231-2242.	0.8	10
573	Identification of a Novel Deactivating Small-Molecule Compound for Fibrogenic Hepatic Stellate Cells. <i>Yonago Acta Medica</i> , 2020, 63, 79-87.	0.3	1



#	ARTICLE	IF	CITATIONS
574	Acute kidney injury in critically ill cirrhotic patients with spontaneous bacterial peritonitis: a comparison of KDIGO and ICA criteria. Archives of Medical Science, 2020, 16, 569-576.	0.4	5
575	Glycyrrheticin Acid-Induced MiR-663a Alleviates Hepatic Stellate Cell Activation by Attenuating the TGF- $\beta$ 2/Smad Signaling Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	13
576	Favorable outcome of adjunctive traditional Chinese medicine therapy in liver cirrhosis: A large cohort study in Southwest China. Complementary Therapies in Medicine, 2020, 51, 102446.	1.3	11
577	Liver Fibrosis and Inflammation under the Control of ERK2. International Journal of Molecular Sciences, 2020, 21, 3796.	1.8	21
578	Screening for abnormal glycosylation in a cohort of adult liver disease patients. Journal of Inherited Metabolic Disease, 2020, 43, 1310-1320.	1.7	6
579	Advances in Magnetic Resonance Elastography of Liver. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 331-340.	0.6	19
580	Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity. ESMO Open, 2020, 5, e000695.	2.0	10
581	Protective and therapeutic effects of nanoliposomal quercetin on acute liver injury in rats. BMC Pharmacology & Toxicology, 2020, 21, 11.	1.0	16
582	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. International Journal of Medical Sciences, 2020, 17, 874-880.	1.1	5
583	Exercise Training Attenuates Cirrhotic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2021, 14, 674-684.	1.1	5
584	Assessment in the Survival Outcome After Transarterial Chemoembolization Combined with Cryoablation for Hepatocellular Carcinoma (Diameter > 4cm) Based on the Albumin-Bilirubin Grade and Platelet-Albumin-Bilirubin $\alpha$ -Zgrade: $\alpha$ -Z A Preliminary Study. Cancer Management and Research, 2020, Volume 12, 1373-1385.	0.9	4
585	Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice. Hepatology, 2020, 72, 2090-2108.	3.6	47
586	Liver Stiffness Measured with Two-dimensional Shear-Wave Elastography Is Predictive of Liver-related Events in Patients with Chronic Liver Disease Due to Hepatitis B Viral Infection. Radiology, 2020, 295, 353-360.	3.6	20
587	Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. Journal of Clinical Medicine, 2020, 9, 643.	1.0	2
588	Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. Clinical Gastroenterology and Hepatology, 2020, 18, 2564-2572.e1.	2.4	55
589	Significant improvement in portal-systemic liver failure symptoms and successful management of portal-splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy. Hepatology Research, 2020, 50, 1201-1208.	1.8	6
590	Association between periodontal disease, tooth loss and liver diseases risk. Journal of Clinical Periodontology, 2020, 47, 1053-1063.	2.3	29
591	Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised controlled trial in China. BMJ Open, 2020, 10, e030960.	0.8	3

#	ARTICLE	IF	CITATIONS
593	Granulocyte colony-stimulating factor with or without stem or progenitor cell infusion for people with compensated or decompensated advanced chronic liver disease. The Cochrane Library, 0, , .	1.5	1
594	Nonselective $\beta$ -Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. <i>Advances in Therapy</i> , 2020, 37, 1452-1463.	1.3	12
595	A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis. <i>Journal of Ethnopharmacology</i> , 2020, 253, 112689.	2.0	41
596	Predictive value of insulin-like growth factor 1-Child-Turcotte-Pugh score for mortality in patients with decompensated cirrhosis. <i>Clinica Chimica Acta</i> , 2020, 505, 141-147.	0.5	4
597	Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 18.	1.8	13
598	Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures. <i>Frontiers in Pharmacology</i> , 2020, 11, 67.	1.6	22
599	Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy. <i>Pharmacological Research</i> , 2020, 155, 104720.	3.1	100
600	The stiffness of living tissues and its implications for tissue engineering. <i>Nature Reviews Materials</i> , 2020, 5, 351-370.	23.3	756
601	The stratification of cirrhosis. <i>Hepatology Research</i> , 2020, 50, 535-541.	1.8	14
602	Using a single abdominal computed tomography image to differentiate five contrast-enhancement phases: A machine-learning algorithm for radiomics-based precision medicine. <i>European Journal of Radiology</i> , 2020, 125, 108850.	1.2	13
603	Ageing-Related Molecular Pathways in Chronic Cholestatic Conditions. <i>Frontiers in Medicine</i> , 2019, 6, 332.	1.2	9
604	S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. <i>Gut</i> , 2020, 69, 1841-1854.	6.1	50
605	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2020, 1, CD013123.	1.5	11
606	Whole Slide Imaging and Its Applications to Histopathological Studies of Liver Disorders. <i>Frontiers in Medicine</i> , 2019, 6, 310.	1.2	31
607	Are Liver Pericytes Just Precursors of Myofibroblasts in Hepatic Diseases? Insights from the Crosstalk between Perivascular and Inflammatory Cells in Liver Injury and Repair. <i>Cells</i> , 2020, 9, 188.	1.8	15
608	Can portal hypertension and hepatic decompensation be predicted?. <i>Journal of Gastroenterology</i> , 2020, 55, 662-663.	2.3	1
609	A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis. <i>BMC Gastroenterology</i> , 2020, 20, 15.	0.8	11
610	Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation. <i>Transplantation Proceedings</i> , 2020, 52, 89-96.	0.3	1

#	ARTICLE	IF	CITATIONS
611	The effects of microgravity on differentiation and cell growth in stem cells and cancer stem cells. <i>Stem Cells Translational Medicine</i> , 2020, 9, 882-894.	1.6	51
612	Comorbidities and Outcome of Alcoholic and Non-Alcoholic Liver Cirrhosis in Taiwan: A Population-Based Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2825.	1.2	5
613	Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. <i>Diagnostics</i> , 2020, 10, 238.	1.3	14
614	Quantification of liver extracellular volume using dual-energy CT: utility for prediction of liver-related events in cirrhosis. <i>European Radiology</i> , 2020, 30, 5317-5326.	2.3	21
615	Animal models for liver disease – A practical approach for translational research. <i>Journal of Hepatology</i> , 2020, 73, 423-440.	1.8	139
616	Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding. <i>Annals of Translational Medicine</i> , 2020, 8, 340-340.	0.7	9
617	MicroRNA-489-3p Represses Hepatic Stellate Cells Activation by Negatively Regulating the JAG1/Notch3 Signaling Pathway. <i>Digestive Diseases and Sciences</i> , 2021, 66, 143-150.	1.1	9
618	Prognosis of endotherapy versus splenectomy and devascularization for variceal bleeding in patients with hepatitis B-related cirrhosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 2620-2628.	1.3	4
619	Novel imaging-based approaches for predicting the hepatic venous pressure gradient in a porcine model of liver cirrhosis and portal hypertension. <i>Life Sciences</i> , 2021, 264, 118710.	2.0	2
620	Derivation and validation of a simple anthropometric equation to predict fat-free mass in patients with chronic hepatitis C. <i>Clinical Nutrition</i> , 2021, 40, 1281-1288.	2.3	5
621	Outcomes of pregnancy in Child A liver cirrhotic patients: A retrospective multicenter study. <i>Advances in Digestive Medicine</i> , 2021, 8, 98-104.	0.1	1
622	Color Doppler Ultrasound in Portal Hypertension. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 7-14.	0.8	5
623	Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 584-592.	1.8	51
624	The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis. <i>World Journal of Surgery</i> , 2021, 45, 562-570.	0.8	4
625	A lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis modulates hepatic stellate cell (HSC) activation. <i>Toxicology Letters</i> , 2021, 336, 21-31.	0.4	9
626	Sustained off therapy response after pegylated interferon favours functional cure and no disease progression in chronic hepatitis B. <i>Liver International</i> , 2021, 41, 288-294.	1.9	6
627	Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 167-180.	8.2	97
628	Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1188-1199.	1.8	70

#	ARTICLE	IF	CITATIONS
629	Quantitative MRI of the liver: Evaluation of extracellular volume fraction and other quantitative parameters in comparison to MR elastography for the assessment of hepatopathy. <i>Magnetic Resonance Imaging</i> , 2021, 77, 7-13.	1.0	8
630	Non-invasive assessment of cirrhosis using multiphasic dual-energy CT iodine maps: correlation with model for end-stage liver disease score. <i>Abdominal Radiology</i> , 2021, 46, 1931-1940.	1.0	2
631	Myocardial Dysfunction in Cirrhotic Cardiomyopathy is Associated with Alterations of Phospholamban Phosphorylation and IL-6 Levels. <i>Archives of Medical Research</i> , 2021, 52, 284-293.	1.5	11
632	<i>Codonopsis bulleyana</i> Forest ex Diels (cbFeD) effectively attenuates hepatic fibrosis in CCl <sub>4</sub> -induced fibrotic mice model. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110960.	2.5	1
633	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1109-1116.	1.8	112
634	Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock. <i>American Journal of Emergency Medicine</i> , 2021, 40, 70-76.	0.7	10
635	High sucrose diet attenuates oxidative stress, inflammation and liver injury in thioacetamide-induced liver cirrhosis. <i>Life Sciences</i> , 2021, 267, 118944.	2.0	13
636	Chronic facial eczema in sheep: description of gross and histological changes in the liver and association with serum gamma-glutamyltransferase activity at the time of sporidesmin intoxication. <i>New Zealand Veterinary Journal</i> , 2021, 69, 104-112.	0.4	5
637	Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 217-233.	1.4	37
638	Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis. <i>Journal of Digestive Diseases</i> , 2021, 22, 31-40.	0.7	8
639	Prognostic role of spleen volume measurement using computed tomography in patients with compensated chronic liver disease from hepatitis B viral infection. <i>European Radiology</i> , 2021, 31, 1432-1442.	2.3	13
640	Long-term albumin administration in patients with cirrhosis and ascites: A meta-analysis of randomized controlled trials. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 609-617.	1.4	14
641	New prognostic score based on galectin-3 has similar performance to model for end-stage liver disease and sodium score in patients with stable decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2021, 34, 728-735.	0.4	1
643	Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. <i>Hepatology International</i> , 2021, 15, 155-165.	1.9	16
644	Impaired antibacterial response of liver sinusoidal V $\beta$ <sup>39</sup> +V $\beta$ <sup>2</sup> + T cells in patients with chronic liver disease. <i>Gut</i> , 2021, , gutjnl-2020-322182.	6.1	3
645	Liver Cirrhosis Complications Management at the Emergency Department. <i>Reviews on Recent Clinical Trials</i> , 2021, 15, 331-338.	0.4	3
646	Essential oil from the raw and vinegar-processed <i>Rhizoma Curcumae</i> ameliorate CCl <sub>4</sub> -induced liver fibrosis: integrating network pharmacology and molecular mechanism evaluation. <i>Food and Function</i> , 2021, 12, 4199-4220.	2.1	12
647	Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching. <i>PLoS ONE</i> , 2021, 16, e0246364.	1.1	1

#	ARTICLE	IF	CITATIONS
648	Quantitative Susceptibility Mapping versus R2*-based Histogram Analysis for Evaluating Liver Fibrosis: Preliminary Results. <i>Magnetic Resonance in Medical Sciences</i> , 2022, 21, 609-622.	1.1	5
649	Infective endocarditis in patients with liver cirrhosis: a systematic review. <i>Journal of Chemotherapy</i> , 2021, 33, 443-451.	0.7	4
650	Treatment of Liver Cirrhosis with PVT. <i>Advances in Clinical Medicine</i> , 2021, 11, 2920-2925.	0.0	0
651	Hepatic Vein Contrast-Enhanced Ultrasound Subharmonic Imaging Signal as a Screening Test for Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4354-4360.	1.1	9
652	EFFICACY OF L-ORNITHINE L-ASPARTATE IN PATIENTS WITH ESOPHAGEAL VARICEAL BLEEDING. <i>World of Medicine and Biology</i> , 2021, 17, 112.	0.1	1
653	Noninvasive assessment of liver fibrosis for predicting acute-on-chronic liver failure in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 593-601.	1.9	6
654	Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 1229-1237.	0.9	2
655	Effect of vitamin D deficiency on spontaneous peritonitis in cirrhosis: a meta-analysis. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 10-14.	0.3	2
656	Model for end stage liver disease for prediction of mortality in people with cirrhosis. <i>The Cochrane Library</i> , 0, , .	1.5	0
657	Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. <i>BMJ Open</i> , 2021, 11, e037793.	0.8	20
658	Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. <i>Cells</i> , 2021, 10, 252.	1.8	11
659	Could protein content of Urinary Extracellular Vesicles be useful to detect Cirrhosis in Alcoholic Liver Disease?. <i>International Journal of Biological Sciences</i> , 2021, 17, 1864-1877.	2.6	10
660	QTc interval prolongation in liver cirrhosis with upper gastrointestinal bleeding. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 68-75.	0.1	1
661	Preexistent chronic disorders, often directly affecting pregnancy. , 2021, , 99-174.		0
662	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 70-80.	4.5	67
663	Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1061-1072.	2.3	13
664	Biomaterial-based cell delivery strategies to promote liver regeneration. <i>Biomaterials Research</i> , 2021, 25, 5.	3.2	22
665	Neutrophil count to albumin ratio as a prognostic indicator for HBV-associated decompensated cirrhosis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23730.	0.9	9

#	ARTICLE	IF	CITATIONS
666	Platelet count can predict the grade of esophageal varices in cirrhotic patients: a cross-sectional study. <i>F1000Research</i> , 2021, 10, 101.	0.8	2
667	Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis. <i>European Radiology</i> , 2021, 31, 5840-5850.	2.3	10
668	RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. <i>Communications Biology</i> , 2021, 4, 230.	2.0	15
669	Renal arterial resistance index among subjects with liver cirrhosis in a Nigerian population. <i>Journal of Clinical Ultrasound</i> , 2021, 49, 538-545.	0.4	2
670	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	1.6	11
671	Formyl Peptide Receptor 2 Alleviates Hepatic Fibrosis in Liver Cirrhosis by Vascular Remodeling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2107.	1.8	11
672	A combination of pirfenidone and TGF- $\beta$ 2 inhibition mitigates cystic echinococcosis-associated hepatic injury. <i>Parasitology</i> , 2021, 148, 767-778.	0.7	4
673	The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 46.	0.8	8
674	Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. <i>World Journal of Gastroenterology</i> , 2021, 27, 416-427.	1.4	6
675	Lactate and Bilirubin Index: A New Indicator to Predict Critically Ill Cirrhotic Patients' Prognosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	1
676	Activated Hepatic Stellate Cells Induce Infiltration and Formation of CD163+ Macrophages via CCL2/CCR2 Pathway. <i>Frontiers in Medicine</i> , 2021, 8, 627927.	1.2	31
677	OPEN ESOPHAGOGASTRIC DEVASCULARIZATION IN ITS OWN MODIFICATION. CASE SERIES PRELIMINARY REPORT. <i>Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta</i> , 2021, 19, 64-70.	0.0	0
678	Antiplatelet drugs and liver fibrosis. <i>Platelets</i> , 2022, 33, 219-228.	1.1	11
679	Use of Texture Analysis on Noncontrast MRI in Classification of Early Stage of Liver Fibrosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	6
680	Clinical Practice of Hepatorenal Syndrome: A Brief Review on Diagnosis and Management. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 1-7.	0.1	0
681	Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013122.	1.5	10
682	Small extracellular vesicles derived from interferon- $\beta$ 3 pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. <i>Npj Regenerative Medicine</i> , 2021, 6, 19.	2.5	44
683	The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 657-664.	0.2	0



#	ARTICLE	IF	CITATIONS
684	Pathophysiology and Management of Variceal Bleeding. <i>Drugs</i> , 2021, 81, 647-667.	4.9	18
685	Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area. <i>Journal of Liver Cancer</i> , 2021, 21, 34-44.	0.3	1
686	Impact of TIPS on Splenic Volume and Thrombocytopenia. <i>American Journal of Roentgenology</i> , 2021, 216, 698-703.	1.0	12
687	Liver fibrosis in patients with tetralogy of Fallot, an unrecognised complication?. <i>Cardiology in the Young</i> , 2021, 31, 1796-1806.	0.4	2
688	Stroke and Liver Cirrhosis: A Brief Review of Current Evidence. , 0, , .		0
689	T2 mapping in gadoxetic acid-enhanced MRI: utility for predicting decompensation and death in cirrhosis. <i>European Radiology</i> , 2021, 31, 8376-8387.	2.3	5
690	Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma. <i>British Journal of Radiology</i> , 2021, 94, 20200950.	1.0	18
691	Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). <i>Journal of Digestive Diseases</i> , 2021, 22, 176-186.	0.7	40
693	Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013121.	1.5	7
694	European Working Group on Sarcopenia in Older People (EWGSOP2) Criteria With Population-Based Skeletal Muscle Index Best Predicts Mortality in Asians With Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 52-60.	0.4	15
695	The MSPâ€“RON pathway regulates liver fibrosis through transforming growth factor betaâ€“dependent epithelialâ€“mesenchymal transition. <i>Liver International</i> , 2021, 41, 1956-1968.	1.9	3
696	Diagnostic Accuracy of the Forns Score for Liver Cirrhosis in Patients With Chronic Viral Hepatitis. <i>Cureus</i> , 2021, 13, e14477.	0.2	2
697	Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments. <i>Hepatology Communications</i> , 2021, 5, 1125-1137.	2.0	18
698	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013155.	1.5	14
699	Highly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients. <i>Immunology Letters</i> , 2021, 232, 9-19.	1.1	16
700	Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPAR $\beta$ . <i>British Journal of Pharmacology</i> , 2021, 178, 2443-2460.	2.7	15
701	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 441-460.	1.0	2
702	Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis. <i>Scientific Reports</i> , 2021, 11, 10535.	1.6	4

#	ARTICLE	IF	CITATIONS
703	Usefulness of International Normalized Ratio to Albumin Ratio for Evaluation of Mortality in Hepatitis B Virus-Associated Decompensated Cirrhosis. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	7
704	Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23775.	0.9	1
705	Association between aldehyde dehydrogenase 2 gene rs671 G>A polymorphism and alcoholic liver cirrhosis in southern Chinese Hakka population. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23855.	0.9	10
706	Alterations in Autophagy and Mammalian Target of Rapamycin (mTOR) Pathways Mediate Sarcopenia in Patients with Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 510-518.	0.4	7
707	The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. <i>Seminars in Liver Disease</i> , 2021, 41, 213-224.	1.8	13
708	A radiomics-based model to classify the etiology of liver cirrhosis using gadoxetic acid-enhanced MRI. <i>Scientific Reports</i> , 2021, 11, 10778.	1.6	10
709	Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. <i>Cancers</i> , 2021, 13, 2270.	1.7	6
710	Material decomposition using iodine quantification on spectral CT for characterising nodules in the cirrhotic liver: a retrospective study. <i>European Radiology Experimental</i> , 2021, 5, 22.	1.7	3
711	Effectiveness of sepsis bundle application and outcomes predictors to cirrhotic patients with septic shock. <i>BMC Infectious Diseases</i> , 2021, 21, 483.	1.3	3
712	Ethical Issues Which Have Prevented the U.S. from Maximizing Quality of Life Years. , 0, , .		1
713	The Role of the Microbiome in Liver Cancer. <i>Cancers</i> , 2021, 13, 2330.	1.7	16
714	Histological sub-classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C. <i>Liver International</i> , 2021, 41, 1608-1613.	1.9	3
715	Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. <i>Life Sciences</i> , 2021, 272, 119203.	2.0	13
716	The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6900.	1.8	32
717	All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study. <i>BMC Public Health</i> , 2021, 21, 970.	1.2	26
718	Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 460-468.	0.6	3
719	Differential production of interleukin-6 and tumor necrosis factor- $\alpha$ in primary rat astrocyte cultures using two distinct methods of microglia elimination. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 192-201.	0.5	1
720	Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 207-214.	0.6	11



#	ARTICLE	IF	CITATIONS
721	Reduced Energy Metabolism Impairs T Cell-Dependent B Cell Responses in Patients With Advanced HBV-Related Cirrhosis. <i>Frontiers in Immunology</i> , 2021, 12, 660312.	2.2	5
723	A novel radiomicsâ€‘platelet nomogram for the prediction of gastroesophageal varices needing treatment in cirrhotic patients. <i>Hepatology International</i> , 2021, 15, 995-1005.	1.9	6
724	Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1141-1151.	0.6	2
725	Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics. <i>Cells</i> , 2021, 10, 1596.	1.8	33
726	Diagnostic Potential of Low Serum Platelet, Albumin and Prolong PT-INR for Overactive Bladder and Nocturia in Chronic Hepatitis-Related Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2838.	1.0	6
727	Does liver cirrhosis affect the surgical outcome of primary colorectal cancer surgery? A meta-analysis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 167.	0.8	22
728	Preoperative Fibrosis-4 (FIB-4) Evaluation May Be Helpful to Evaluate Prognosis of Gastric Cancer Patients Undergoing Operation: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 655343.	1.3	3
729	Eliciting and Understanding Primary Care and Specialist Mental Models of Cirrhosis Care: A Cognitive Task Analysis Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	4
730	Comparison of Anthropometry, Bioelectrical Impedance, and Dual-energy X-ray Absorptiometry for Body Composition in Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 467-474.	0.4	10
731	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. <i>JHEP Reports</i> , 2021, 3, 100262.	2.6	15
732	VIRUS-ASSOCIATED HEPATOCELLULAR LIVER CANCER. <i>Hepatology and Gastroenterology</i> , 2021, 5, 17-24.	0.1	5
733	Survival of Patients with Lung Cancer in the Setting of Liver Cirrhosis: A Multicenter Propensity Score Matching Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 4373-4381.	0.9	0
734	Towards a new definition of decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 202-207.	1.8	66
735	Type 2 diabetes mellitus increases liver transplant-free mortality in patients with cirrhosis: A systematic review and meta-analysis. <i>World Journal of Clinical Cases</i> , 2021, 9, 5514-5525.	0.3	3
736	Gender-Specific Risk Factors Contributing to Mortality in Patients Hospitalized With Alcoholic Cirrhosis. <i>Cureus</i> , 2021, 13, e16271.	0.2	1
737	Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 598-613.	0.4	19
738	Liver Stiffness Is a Predictor of Rebleeding in Patients With Hepatitis B-Related Cirrhosis: A Real-World Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 690825.	1.2	6
739	Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8139.	1.8	38

#	ARTICLE	IF	CITATIONS
740	Association Between Kidney Dysfunction Types and Mortality Among Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3426-3435.	1.1	8
741	Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". <i>Journal of Clinical Medicine</i> , 2021, 10, 3340.	1.0	6
742	Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1135-e1148.	2.4	26
743	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021, 75, S67-S81.	1.8	107
744	B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101698.	0.7	7
745	Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs. <i>Frontiers in Microbiology</i> , 2021, 12, 694967.	1.5	17
746	Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 481-492.	1.9	23
747	Circular RNA as An Epigenetic Regulator in Chronic Liver Diseases. <i>Cells</i> , 2021, 10, 1945.	1.8	35
748	Enzymatic liver function measured by LiMAx is superior to current standard methods in predicting transplant-free survival after TIPS implantation. <i>Scientific Reports</i> , 2021, 11, 13834.	1.6	5
749	Autonomic regulation of imbalance-induced myocardial fibrosis and its mechanism in rats with cirrhosis. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1040.	0.8	2
750	<i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4687-4696.	1.4	6
751	Evaluation of Sarcopenia and Investigation of Prognostic Value Of Sarcopenia Using Psoas Muscle Area on Computed Tomography in Patients with Liver Cirrhosis. <i>European Journal of Medical and Educational Technologies</i> , 2021, 14, em2111.	0.7	0
752	Association of Low High-Density Lipoprotein Cholesterol Levels with Poor Outcomes in Hepatitis B-Associated Decompensated Cirrhosis Patients. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	6
753	Integrated Analysis of Hepatic miRNA and mRNA Expression Profiles in the Spontaneous Reversal Process of Liver Fibrosis. <i>Frontiers in Genetics</i> , 2021, 12, 706341.	1.1	2
754	Effects of transjugular intrahepatic portosystemic shunt treatment of patients with liver cirrhosis and portal hypertension. <i>Medicine (United States)</i> , 2021, 100, e26610.	0.4	3
756	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	1.0	13
757	The Emerging Role of Stress Granules in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9428.	1.8	8
758	Pentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 581-585.	0.4	3

#	ARTICLE	IF	CITATIONS
759	Kidney Failure after Liver Transplantation. <i>Transplantation</i> , 2021, 2, 315-335.	0.3	3
760	Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. <i>Journal of Hepatology</i> , 2021, 75, 1420-1433.	1.8	70
762	Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis. <i>Future Science OA</i> , 2021, 7, FSO717.	0.9	1
763	The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8309.	1.8	15
764	Significance of Circulating Cell-Free DNA Species in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8849.	1.8	6
765	Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100355.	2.6	15
766	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
767	The prognostic utility of ascites sodium level in cirrhotic patients. <i>Akademik Gastroenteroloji Dergisi</i> , 0, , 1-5.	0.0	0
768	Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure. <i>Hepatology International</i> , 2021, 15, 1093-1102.	1.9	8
769	Significance of hepatocyte atypia in liver fine needle aspiration. <i>Diagnostic Cytopathology</i> , 2021, , .	0.5	2
770	Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. <i>Bladder Cancer</i> , 2021, 7, 261-278.	0.2	1
771	The impact of alcohol abuse on the development of non-communicable diseases (analytical review). <i>Obshchestvenoe Zdorov'e</i> , 2021, 1, 48-61.	0.2	3
772	Liver Fibrosis Staging with Gadolinium Ethoxybenzyl Diethylenetriamine Penta-Acetic Acid-enhanced: A Systematic Review and Meta-analysis. <i>Current Medical Imaging</i> , 2021, 17, 854-863.	0.4	2
773	Functional role of miR-155 in physiological and pathological processes of liver injury (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	11
774	Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 327-336.	0.7	7
775	Collaterals in portal hypertension: anatomy and clinical relevance. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3867-3881.	1.1	15
776	Free-breathing multitasking multi-echo MRI for whole-liver water-specific T <sub>1</sub> , proton density fat fraction, and quantification. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 120-137.	1.9	16
777	Impact of portal hypertension on short- and long-term outcomes after liver resection for intrahepatic cholangiocarcinoma: A propensity score matching analysis. <i>Cancer Medicine</i> , 2021, 10, 6985-6997.	1.3	4

#	ARTICLE	IF	CITATIONS
778	Oral delivery of a <i>Lactococcus lactis</i> expressing extracellular TGF $\beta$ 2R2 alleviates hepatic fibrosis. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 6007-6018.	1.7	10
779	In vivo hepatoprotective effect of <i>Morinda elliptica</i> stem extract against liver fibrosis induced by thioacetamide. <i>Environmental Toxicology</i> , 2021, 36, 2404-2413.	2.1	8
780	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	1.8	36
781	Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10372.	1.8	11
782	Effects of Preoperative Oral Carbohydrate on Cirrhotic Patients under Endoscopic Therapy with Anesthesia: A Randomized Controlled Trial. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	2
783	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 138-146.	0.2	8
784	Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 406-415.	2.3	4
785	Doppler Ultrasound to assess the pharmacodynamic effects of splanchnic vasoactive compounds. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	0
786	Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
787	Postoperative Complications Associated with Moderate Sedation in Endoscopic Procedures Among Patients with Cirrhosis. <i>Medical Science Monitor</i> , 2021, 27, e933082.	0.5	2
788	Targeting Gut—Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. <i>Livers</i> , 2021, 1, 147-179.	0.8	3
789	A review of the health implications of heavy metals and pesticide residues on khat users. <i>Bulletin of the National Research Centre</i> , 2021, 45, .	0.7	12
790	New prognostic factor for hepatitis B virus—related decompensated cirrhosis: Ratio of monocytes to HDL—cholesterol. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24007.	0.9	6
791	Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review. <i>JHEP Reports</i> , 2021, 3, 100370.	2.6	26
792	Prognosis of patients with liver cirrhosis: A multi—center retrospective observational study. <i>Hepatology Research</i> , 2021, 51, 1196-1206.	1.8	8
793	Discovery of a Potential Liver Fibrosis Inhibitor from a Mushroom Endophytic Fungus by Genome Mining of a Silent Biosynthetic Gene Cluster. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 11303-11310.	2.4	1
794	Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1948-1958.	2.9	59
795	Liver Impairment—The Potential Application of Volatile Organic Compounds in Hepatology. <i>Metabolites</i> , 2021, 11, 618.	1.3	19

#	ARTICLE	IF	CITATIONS
796	Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 69-77.	1.0	4
797	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	5.8	21
798	HCC and Molecular Targeting Therapies: Back to the Future. <i>Biomedicines</i> , 2021, 9, 1345.	1.4	22
799	Identification of plasma lncRNA-ATB levels in hepatitis B virus-related cirrhosis and non-cirrhotic chronic hepatitis B patients. <i>Virus Research</i> , 2021, 303, 198503.	1.1	7
800	Machine learning algorithms to predict the 1-year unfavourable prognosis for advanced schistosomiasis. <i>International Journal for Parasitology</i> , 2021, 51, 959-965.	1.3	10
801	Treatment of refractory ascites with an automated low flow ascites pump in patients awaiting liver transplantation. <i>Journal of Liver Transplantation</i> , 2021, 4, 100037.	0.2	2
802	Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives. <i>Mechanisms of Ageing and Development</i> , 2021, 199, 111572.	2.2	38
803	Noninvasive assessment of clinically significant portal hypertension using $^{125}\text{Tl}$ of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. <i>European Journal of Radiology</i> , 2021, 144, 109958.	1.2	4
804	Ubiquitin pathways regulate the pathogenesis of chronic liver disease. <i>Biochemical Pharmacology</i> , 2021, 193, 114764.	2.0	13
805	The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases. , 2021, 228, 107941.		17
806	QTc interval prolongation in liver cirrhosis with upper gastrointestinal bleeding. <i>Medicina Clínica</i> , 2021, 156, 68-75.	0.3	1
807	Comparing CLIF-C ACLF, CLIF-C ACLFlactate, and CLIF-C ACLF-D Prognostic Scores in Acute-on-Chronic Liver Failure Patients by a Single-Center ICU Experience. <i>Journal of Personalized Medicine</i> , 2021, 11, 79.	1.1	6
808	Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 148-155.	6.1	98
809	Predicting Microbe-Disease Association Based on Multiple Similarities and LINE Algorithm. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2022, 19, 2399-2408.	1.9	8
810	Subharmonic Scattering of SonoVue Microbubbles Within 10-40-mmHg Overpressures <i>In Vitro</i> . <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2021, 68, 3583-3591.	1.7	7
811	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD013125.	1.5	21
812	Assessment of Liver Fibrotic Insults <i>In Vitro</i> . <i>Methods in Molecular Biology</i> , 2015, 1250, 391-401.	0.4	11
813	Fibrinogen $\beta$ -Chain as a Serum Marker of Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 493-511.	0.0	2

#	ARTICLE	IF	CITATIONS
814	Liver Failure, Acute-on-Chronic. , 2020, , 436-443.		1
815	Treatment profile and long-term outcome of intensive care unit-admitted patients with liver cirrhosis or other liver disease in relation to alcohol consumption. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 180-187.	0.6	2
816	Cirrhotic Patients Admitted to the ICU With Septic Shock: Factors Predicting Short and Long-Term Outcome. <i>Shock</i> , 2019, 52, 408-413.	1.0	12
818	Collagen proportionate area predicts clinical outcomes in patients with alcoholá€related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1728-1739.	1.9	27
819	Diagnostic Accuracy of APRI, AAR, FIB-4, FI, and King Scores for Diagnosis of Esophageal Varices in Liver Cirrhosis: A Retrospective Study. <i>Medical Science Monitor</i> , 2015, 21, 3961-3977.	0.5	42
820	Improvement in Quality of Life and Activities of Daily Living in Patients with Liver Cirrhosis with the Use of Health Education and Patient Health Empowerment. <i>Medical Science Monitor</i> , 2019, 25, 4602-4608.	0.5	11
821	Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy. <i>Medical Science Monitor</i> , 2020, 26, e924040.	0.5	5
822	Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy. <i>World Journal of Clinical Cases</i> , 2018, 6, 995-1006.	0.3	16
823	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0116768.	1.1	21
824	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.	1.1	34
825	Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184404.	1.1	10
826	Antihepatic Fibrosis Drugs in Clinical Trials. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-9.	0.7	21
827	The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 2026-2035.	0.2	37
828	Antifibrotic effects of total or partial application of amniotic membrane in hepatic fibrosis. <i>Anais Da Academia Brasileira De Ciencias</i> , 2019, 91, e20190220.	0.3	8
829	Occurrence, diagnosis and management of hepatic fibrosis and cirrhosis: An updated literature review. <i>Archives of Hepatitis Research</i> , 2019, 5, 022-026.	0.4	2
830	Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways. <i>Aging</i> , 2020, 12, 10614-10632.	1.4	19
831	A model integrating donor gene polymorphisms predicts fibrosis after liver transplantation. <i>Aging</i> , 2021, 13, 1264-1275.	1.4	9
832	HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 62789-62796.	0.8	13

#	ARTICLE	IF	CITATIONS
833	RSPOs facilitated HSC activation and promoted hepatic fibrogenesis. <i>Oncotarget</i> , 2016, 7, 63767-63778.	0.8	24
834	Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation. <i>Oncotarget</i> , 2017, 8, 40486-40500.	0.8	26
835	Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis. <i>Oncotarget</i> , 2017, 8, 88951-88964.	0.8	15
836	Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 5397-5405.	0.8	4
837	Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients. <i>Oncotarget</i> , 2019, 10, 2161-2172.	0.8	30
838	Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. <i>Annals of Translational Medicine</i> , 2019, 7, 528-528.	0.7	26
839	Portal pressure monitoringâ€”state-of-the-art and future perspective. <i>Annals of Translational Medicine</i> , 2019, 7, 583-583.	0.7	22
840	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	0.4	6
841	Patient Blood Management: a revolutionary approach to transfusion medicine. <i>Blood Transfusion</i> , 2019, 17, 191-195.	0.3	61
842	Hypoxia-inducible factor may induce the development of liver fibrosis in Buddâ€”Chiari syndrome by regulating CD248/endothelin expression: A hypothesis. <i>Journal of Translational Internal Medicine</i> , 2018, 6, 66-69.	1.0	4
844	Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 158.	4.5	6
845	Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 163-179.	4.5	5
846	Reduction in SNAP-23 Alters Microfilament Organization in Myofibroblastic Hepatic Stellate Cells. <i>Gene Expression</i> , 2020, 20, 25-37.	0.5	3
847	Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 3020.	1.4	35
848	Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. <i>World Journal of Gastroenterology</i> , 2015, 21, 7637.	1.4	96
849	Reversed portal flow: Clinical influence on the long-term outcomes in cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 8894.	1.4	26
850	Albumin and magnetic resonance imaging-liver volume to identify hepatitis B-related cirrhosis and esophageal varices. <i>World Journal of Gastroenterology</i> , 2015, 21, 988.	1.4	18
851	Platelet count combined with right liver volume and spleen volume measured by magnetic resonance imaging for identifying cirrhosis and esophageal varices. <i>World Journal of Gastroenterology</i> , 2015, 21, 10184-10191.	1.4	15



#	ARTICLE	IF	CITATIONS
852	Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World Journal of Gastroenterology, 2016, 22, 72.	1.4	34
853	Pharmacokinetic drug interactions in liver disease: An update. World Journal of Gastroenterology, 2016, 22, 1260.	1.4	62
854	Effect of liver cirrhosis on long-term outcomes after acute respiratory failure: A population-based study. World Journal of Gastroenterology, 2017, 23, 2201.	1.4	9
855	Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis. World Journal of Gastroenterology, 2017, 23, 3133.	1.4	7
856	Wall shear stress in portal vein of cirrhotic patients with portal hypertension. World Journal of Gastroenterology, 2017, 23, 3279.	1.4	17
857	Can a fibrotic liver afford epithelial-mesenchymal transition?. World Journal of Gastroenterology, 2017, 23, 4661.	1.4	28
858	Considerations for bariatric surgery in patients with cirrhosis. World Journal of Gastroenterology, 2018, 24, 3112-3119.	1.4	46
859	Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World Journal of Gastroenterology, 2018, 24, 4356-4368.	1.4	16
860	Gut-liver axis signaling in portal hypertension. World Journal of Gastroenterology, 2019, 25, 5897-5917.	1.4	67
861	Prognostic value of risk scoring systems for cirrhotic patients with variceal bleeding. World Journal of Gastroenterology, 2019, 25, 6668-6680.	1.4	20
862	Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure. World Journal of Gastroenterology, 2020, 26, 1208-1220.	1.4	20
863	Role of T <sub>H</sub> 17 cells in liver diseases and its relationship with intestinal microbiota. World Journal of Gastroenterology, 2020, 26, 2559-2569.	1.4	21
864	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World Journal of Gastroenterology, 2020, 26, 2740-2757.	1.4	14
865	Protective Effects of Curcumin and Ginger on Liver Cirrhosis Induced by Carbon Tetrachloride in Rats. International Journal of Pharmacology, 2016, 12, 361-369.	0.1	8
866	ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2014, 3, 415-8.	0.7	13
867	Lifetime alcohol consumption and severity in alcohol dependence syndrome. Industrial Psychiatry, 2017, 26, 34.	0.3	6
868	The prognoses and postoperative outcomes of patients with both colorectal cancer and liver cirrhosis based on a nationwide cohort in Korea. Annals of Surgical Treatment and Research, 2020, 99, 82.	0.4	5
869	Lessons from a real life experience of rifaximin use in the management of recurrent hepatic encephalopathy. World Journal of Hepatology, 2020, 12, 10-20.	0.8	2

#	ARTICLE	IF	CITATIONS
870	Effect of non-alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis. <i>World Journal of Hepatology</i> , 2020, 12, 1299-1313.	0.8	9
871	Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma. <i>World Journal of Hepatology</i> , 2020, 12, 34-45.	0.8	4
872	Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus. <i>World Journal of Hepatology</i> , 2020, 12, 137-148.	0.8	4
873	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2913.	0.8	4
874	Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard. <i>Hepatitis Monthly</i> , 2016, 16, e31983.	0.1	4
875	Emergency Management of Spontaneous Bacterial Peritonitis – A Clinical Review. <i>Cureus</i> , 2018, 10, e2253.	0.2	10
876	IGF-1 alleviates CCL4-induced hepatic cirrhosis and dysfunction of intestinal barrier through inhibition TLR4/NF- $\kappa$ B signaling mediated by down-regulation HMGB1. <i>Annals of Hepatology</i> , 2021, 26, 100560.	0.6	7
877	Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan. <i>Population Health Metrics</i> , 2021, 19, 36.	1.3	2
878	Comparative Utility of Transient and 2D Shear Wave Elastography for the Assessment of Liver Fibrosis in Clinical Practice. <i>Journal of Digital Imaging</i> , 2021, 34, 1342-1348.	1.6	7
879	Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. <i>Frontiers in Oncology</i> , 2021, 11, 751777.	1.3	2
880	Frailty and the Risk of Acute Kidney Injury Among Patients With Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 910-919.	2.0	8
881	Regulatory T Cells Improved the Anti-cirrhosis Activity of Human Amniotic Mesenchymal Stem Cell in the Liver by Regulating the TGF- $\beta$ 2-Indoleamine 2,3-Dioxygenase Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 737825.	1.8	4
882	Somatic Mosaicism in Biology and Disease. <i>Annual Review of Physiology</i> , 2022, 84, 113-133.	5.6	5
883	Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. <i>Cancers</i> , 2021, 13, 5045.	1.7	8
884	Additional Benefits Conferred by Endoscopic Sclerotherapy to Liver Cirrhosis Patients Receiving Endoscopic Variceal Ligation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-6.	0.5	2
885	Investigation on returning to work in liver cancer survivors in Taiwan: a 5-year follow-up study. <i>BMC Public Health</i> , 2021, 21, 1846.	1.2	3
886	Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. <i>Scientific Reports</i> , 2021, 11, 20506.	1.6	4
887	Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-6.	0.5	2

#	ARTICLE	IF	CITATIONS
888	TRIM proteins in fibrosis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112340.	2.5	6
889	Peripheral edema: diagnostics and treatment. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2014, 2014, 15-22.	0.0	1
890	Fibrinogen Î±-Chain as a Serum Marker of Liver Disease. <i>Exposure and Health</i> , 2015, , 1-20.	2.8	0
891	Chronic Liver Failure. , 2016, , III-4-86-III-4-91.		0
892	Defining Clinical Hints to Predict Decompensation and Altering Paradigm in Patients with Cirrhosis. , 2016, , 89-97.		0
893	Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis. <i>The Cochrane Library</i> , 0, , .	1.5	1
894	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 117-131.	0.1	0
895	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. <i>Biomarkers in Disease</i> , 2017, , 559-580.	0.0	0
896	Profiling Neutrophilâ€™s Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. <i>In Vivo</i> , 2017, 31, 1175-1177.	0.6	1
897	DANTEâ€™s Medical Knowledge: The Case of INFERNO, Canto XXX. <i>Advances in Historical Studies</i> , 2018, 07, 15-21.	0.0	0
898	The Baveno IV Workshop: European Consensus Meeting on Portal Hypertension and Comparison with Japanese Guidelines. , 2019, , 185-191.		0
899	Antifibrotic Therapy for Liver Cirrhosis. , 2019, , 167-189.		0
900	Zinc deficiency correlates to spontaneous bacterial peritonitis in patients with cirrhotic ascites. <i>The Egyptian Journal of Internal Medicine</i> , 2019, 31, 73-77.	0.3	1
901	Model for end-stage liver disease and pneumonia: An improved scoring model for critically ill cirrhotic patients with pneumonia. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 532-540.	0.4	3
902	Wasting Away with Cirrhosis: A Review of Hepatic Sarcopenia. <i>Journal of Renal and Hepatic Disorders</i> , 2019, 3, 40-46.	0.1	0
903	Can Weather Influence the Prevalence of Acute-on-chronic Liver Failure?. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 285-286.	0.7	0
905	Upper Digestive Lesions Not Linked to Portal Hypertension during Cirrhosis: About 82 Cases in the Hepato-Gastroenterology Department of Aristide Le Dantec Hospital. <i>Open Journal of Gastroenterology</i> , 2020, 10, 53-60.	0.1	0
906	Chronic Liver Failure and Acute-on-Chronic Liver Failure. , 2020, , 381-394.		0

#	ARTICLE	IF	CITATIONS
907	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 191-202.	2.0	3
908	Skolosidal Ajanlardan Kaynaklanan Sklerozan Kolanjitin Ānlenmesinde Halofuginon ve Ursodeoksikolik Asidin Etkileri. <i>Mustafa Kemal Āeniversitesi TĀ±p Dergisi</i> , 0, , .	0.1	0
909	&lt;p&gt;Clinical Efficacy and Cost-Effectiveness of Ā <sup>2</sup> -Lactam/Ā <sup>2</sup> -Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 1327-1338.	1.1	2
910	Prediction of esophageal varices in patients with HCV-related cirrhosis using albumin-bilirubin, platelets-albumin-bilirubin score, albumin-bilirubin-platelets grade, and GAR. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	2
911	Liver fibrosis. <i>Vnitřni Lekarství</i> , 2020, 66, e36-e41.	0.1	9
912	Elevated neopterin levels are associated with acute-on-chronic liver failure and mortality in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2020, 52, 753-760.	0.4	1
913	Accurate ultrasonography-based portal pressure assessment in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 931-941.	0.8	0
914	Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by <i>Escherichia coli</i> : A Multicenter Study. <i>Infectious Microbes &amp; Diseases</i> , 2020, 2, 167-172.	0.5	2
915	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	3.6	18
916	Update on bloodâ€based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience. <i>JGH Open</i> , 2021, 5, 1250-1256.	0.7	5
917	The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11680.	1.8	7
918	Bioelectrical impedance vector analysis in patients on the waiting list for liver transplant: Associated factors and prognostic effects. <i>Nutrition</i> , 2022, 94, 111528.	1.1	2
919	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
920	Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases. <i>Biomedicines</i> , 2021, 9, 1563.	1.4	9
922	QTc prolongation in patients of cirrhosis and its relation with disease severity: An observational study from a rural teaching hospital. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 3020.	0.3	6
923	Impact of liver disease on patientsâ€™ quality of life: a mixed methods systematic review protocol. <i>JBI Evidence Synthesis</i> , 2021, 19, 1412-1417.	0.6	1
924	Response to Anand and Sharma. <i>American Journal of Gastroenterology</i> , 2021, 116, 1094-1095.	0.2	0
925	Severity of Non-B and Non-C Hepatitis Versus Hepatitis B and C Associated Chronic Liver Disease: A Retrospective, Observational, Comparative Study. <i>Cureus</i> , 2020, 12, e12294.	0.2	2

#	ARTICLE	IF	CITATIONS
926	Ultrasound Image-Based Diagnosis of Cirrhosis with an End-to-End Deep Learning model. , 2020, , .		3
927	GLUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arquivos De Gastroenterologia, 2020, 57, 381-398.	0.3	5
928	Assessment of Liver Function. , 2020, , 407-426.		0
929	MÃ©todos de detecÃ§Ã£o de fibrose em pacientes cirrÃ³ticos. ParÃ¡ Research Medical Journal, 0, 4, 1-7.	0.2	1
930	Pathobiology of chronic liver disease. , 2020, , 3043-3048.		0
931	PATHOLOGICAL MORPHO-FUNCTIONAL DYSINTEGRATION AS THE KEY PATHOGENETIC MECHANISM OF EXPERIMENTAL LIVER CIRRHOSIS. World of Medicine and Biology, 2020, 16, 159.	0.1	0
932	Features of redox homeostasis in patients with liver cirrhosis (literature review and clinical case) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50	0.0	0
934	Long Noncoding RNAs as Drivers of Acquired Chemoresistance in Hepatocellular Carcinoma. RNA Technologies, 2020, , 199-227.	0.2	0
935	Endoscopic Management of Variceal Bleeding. , 2020, , 1-34.		0
937	Special Indications: Cirrhosis, Inflammatory Bowel Disease, and Organ Transplantation. , 2020, , 19-35.		0
939	H-shaped partial splenorenal shunting with the use of a reinforced graft made of porous polytetrafluoroethylene. Angiologia i Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2020, 26, 103.	0.0	1
940	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. European Journal of Gastroenterology and Hepatology, 2021, 32, 223-229.	0.8	3
942	REDUCED PERIPHERAL AND INSPIRATORY MUSCLE ENDURANCE IN PATIENTS WITH LIVER CIRRHOSIS: A CROSS-SECTIONAL STUDY. Arquivos De Gastroenterologia, 2021, 58, 308-315.	0.3	2
943	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Regional Health - Europe, The, 2022, 12, 100240.	3.0	50
944	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. Clinical and Molecular Hepatology, 2022, 28, 77-90.	4.5	12
945	Prognostic value of neutrophil-to-lymphocyte ratio in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2022, 34, 435-442.	0.8	5
946	Higher intake of whole grains and dietary fiber are associated with lower risk of liver cancer and chronic liver disease mortality. Nature Communications, 2021, 12, 6388.	5.8	31
947	Endoscopic Management of Variceal Bleeding. , 2022, , 1059-1092.		0

#	ARTICLE	IF	CITATIONS
948	The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. <i>Frontiers in Pharmacology</i> , 2021, 12, 771459.	1.6	16
949	The Gastrointestinal Tract in the Elder. , 2020, , 375-404.		0
950	Hepatic Angiography and Vascular Interventional Radiology. <i>Medical Radiology</i> , 2021, , 133-173.	0.0	0
951	Epidemiology of Varices and Variceal Bleeding in Liver Cirrhosis. , 2021, , 1-11.		5
952	Is MELD the best prognostic score in acute variceal bleeding? The jury is still out. <i>Annals of Gastroenterology</i> , 2014, 27, 282-283.	0.4	1
953	Quality of life and factors predictive of burden among primary caregivers of chronic liver disease patients. <i>Annals of Gastroenterology</i> , 2015, 28, 124-129.	0.4	40
954	Metabolic and cardiovascular complications in the liver transplant recipient. <i>Annals of Gastroenterology</i> , 2015, 28, 183-192.	0.4	29
955	Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective cross-sectional study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 5989-98.	1.3	16
956	Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis. <i>Annals of Gastroenterology</i> , 2016, 29, 1-2.	0.4	31
957	FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. <i>International Journal of Clinical and Experimental Medicine</i> . 2015, 8, 20876-82.	1.3	9
958	Lyn kinase enhanced hepatic fibrosis by modulating the activation of hepatic stellate cells. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2865-2877.	0.0	8
959	Thymoquinone restores liver fibrosis and improves oxidative stress status in a lipopolysaccharide-induced inflammation model in rats. <i>Avicenna Journal of Phytomedicine</i> , 2017, 7, 502-510.	0.1	10
960	Autologous Bone Marrow Stem Cell Transplantation in Liver Cirrhosis after Correcting Nutritional Anomalies, A Controlled Clinical Study. <i>Cell Journal</i> , 2019, 21, 268-273.	0.2	4
962	Down-regulation of LncRNA UCA1 alleviates liver injury in rats with liver cirrhosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 455-465.	0.5	3
963	Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3819-3829.	0.5	1
964	Interleukin-26 promotes the proliferation and activation of hepatic stellate cells to exacerbate liver fibrosis by the TGF- $\beta$ 1/Smad2 signaling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 4271-4279.	0.5	2
965	Characteristics of peripheral and intrahepatic regulatory B cells in HBV-related liver cirrhosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4545-4551.	0.5	1
967	Clinical characteristics and risk factors of patients with flupirtine-induced liver cirrhosis complicated with upper gastrointestinal bleeding. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 5582-5588.	0.0	1

#	ARTICLE	IF	CITATIONS
968	Physiologically Based Modeling of the Effect of Physiological and Anthropometric Variability on Indocyanine Green Based Liver Function Tests. <i>Frontiers in Physiology</i> , 2021, 12, 757293.	1.3	2
969	Albumin Substitution in Decompensated Liver Cirrhosis: Don't Forget Zinc. <i>Nutrients</i> , 2021, 13, 4011.	1.7	10
970	Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol-Induced Liver Damage. <i>Hepatology Communications</i> , 2022, 6, 513-525.	2.0	6
971	Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. <i>World Journal of Cardiology</i> , 2021, 13, 599-607.	0.5	5
972	Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matching analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1078-1086.	0.5	1
973	Diagnosis of liver cirrhosis with two-dimensional shear wave elastography in biliary atresia before Kasai portoenterostomy. <i>Pediatric Surgery International</i> , 2022, 38, 209-215.	0.6	5
974	Ginsenoside PPD inhibit the activation of HSCs by directly targeting TGF $\beta$ 1R1. <i>International Journal of Biological Macromolecules</i> , 2022, 194, 556-562.	3.6	3
975	Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2649-2658.	0.8	3
976	Platelet count can predict the grade of esophageal varices in cirrhotic patients: a cross-sectional study. <i>F1000Research</i> , 0, 10, 101.	0.8	1
977	The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. <i>Cancers</i> , 2021, 13, 5719.	1.7	14
978	High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis—An Observational Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 800-807.	0.4	2
979	Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. <i>Biomarkers</i> , 2022, 27, 13-21.	0.9	7
980	Assessing the progression of segmental fibrosis in chronic liver disease using extracellular volume fractions. <i>European Journal of Radiology</i> , 2021, 145, 110033.	1.2	4
981	Ultrasound Pressure Estimation for Diagnosing Portal Hypertension in Patients Undergoing Dialysis for Chronic Kidney Disease. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 2181-2189.	0.8	3
982	Diagnostic Tests: Testing for cirrhosis. <i>Australian Prescriber</i> , 2021, 44, 197-199.	0.5	2
983	The EASL—Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
984	Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 102-111.	0.9	7
985	Comparison of lymphocyte-to-monocyte ratio with Child-Pugh and PELD/MELD scores to predict the outcome of children with cirrhosis. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 351-357.	0.6	3



#	ARTICLE	IF	CITATIONS
986	Giant Spider Angioma Following Cirrhosis in HIV-Infected Individuals. American Journal of the Medical Sciences, 2022, , .	0.4	0
987	Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters. United European Gastroenterology Journal, 2022, 10, 8-9.	1.6	3
988	Hepatic inflammation and liver fibrogenesis: A potential target for the treatment of cystic echinococcosis-associated hepatic injury. Acta Tropica, 2022, 226, 106265.	0.9	4
989	ULTRASOUND ELASTOGRAPHY FOR NONINVASIVE EVALUATION OF LIVER CYRROSIS AND PORTAL HYPERTENSION. Problemy ZdorovĚ1Äč I Ä"ologii, 2017, , 105-110.	0.0	1
990	MAJOR DEPRESSIVE DISORDER IS ASSOCIATED WITH TYPE 2 DIABETES IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. Arquivos De Gastroenterologia, 2021, 58, 476-482.	0.3	1
991	The continued decline of plasma transfusions in Taiwan: An 11-year population-based study. Vox Sanguinis, 2022, 117, 535-544.	0.7	1
992	Diagnostic challenges in patients with alcohol-related liver disease. Zeitschrift Fur Gastroenterologie, 2022, 60, 45-57.	0.2	2
993	A strategy of vascular-targeted therapy for liver fibrosis. Hepatology, 2022, 76, 660-675.	3.6	29
994	A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes. Journal of Clinical and Translational Hepatology, 2022, 10, 891-900.	0.7	2
995	Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response. Clinical and Experimental Medicine, 2022, , 1.	1.9	2
996	Predictive value of liver cirrhosis using metabolite biomarkers of bile acid in the blood. Medicine (United States), 2022, 101, e28529.	0.4	3
997	Reprogramming the spleen into a functioning "liver"™ in vivo. Gut, 2022, 71, 2325-2336.	6.1	9
998	Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt. Journal of Clinical Medicine, 2022, 11, 461.	1.0	2
999	Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. Life Sciences, 2022, 289, 120192.	2.0	2
1000	Comparing Frequency of Cardiovascular Autonomic Neuropathy in Diabetic Cirrhotic with Non Diabetic Cirrhotic Patients. Pakistan Biomedical Journal, 2021, 5, .	0.0	0
1001	Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography. European Journal of Clinical Investigation, 2022, 52, e13750.	1.7	10
1002	Liver Fibrosis"From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814496.	1.2	9
1003	High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis. Expert Review of Gastroenterology and Hepatology, 2022, 16, 193-199.	1.4	9

#	ARTICLE	IF	CITATIONS
1004	Quantification of liver extracellular volume using dual-energy CT for ruling out high-risk varices in cirrhosis. <i>European Journal of Radiology</i> , 2022, 148, 110151.	1.2	1
1005	HGF/heparin-immobilized decellularized liver matrices as novel hepatic patches for hepatocyte regeneration in an acute liver injury model. <i>Biochemical Engineering Journal</i> , 2022, 180, 108354.	1.8	4
1007	Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 306-316.	1.0	4
1008	A systematic review of auxiliary liver transplantation of small-for-size grafts in patients with chronic liver disease. <i>JHEP Reports</i> , 2022, 4, 100447.	2.6	3
1009	A prediction model for 30-day deaths of cirrhotic patients in intensive care unit hospitalization. <i>Medicine (United States)</i> , 2022, 101, e28752.	0.4	1
1010	Mineralocorticoid receptors in non-alcoholic fatty liver disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3165-3177.	2.7	8
1011	FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2. <i>Gut</i> , 2022, 71, 2539-2550.	6.1	55
1013	Hepatic injuries resulting from chronic alcohol abuse identified by forensics. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 62, 819-827.	0.4	0
1014	CircCHD2/miR-200b-3p/HLF Axis Promotes Liver Cirrhosis. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2022, 41, 1-10.	0.6	3
1015	CK19 and OV6 Expressions in the Liver of 2-AAF/CCl4 Rat Model. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 340-345.	0.1	0
1016	Evaluation of adrenal function in hemodynamically stable patients with liver cirrhosis. <i>Clinical and Experimental Hepatology</i> , 2022, 8, 78-83.	0.6	1
1018	Hepatoprotective potential of bioflavonoids. <i>Studies in Natural Products Chemistry</i> , 2022, , 259-285.	0.8	8
1019	Decompensated chronic liver disease: A review of current concepts and management guidelines. <i>Current Medicine Research and Practice</i> , 2022, 12, 26.	0.1	0
1020	Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 353-372.	2.7	23
1021	High Albumin Level Is Associated With Regression of Glucose Metabolism Disorders Upon Resolution of Acute Liver Inflammation in Hepatitis B-Related Cirrhosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 721138.	1.8	3
1022	Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 839456.	1.2	6
1023	Pacient s jatern-cirh-zou na intern-odd-len; intervence p-Åpadn-cho ab-zu alkoholu. <i>Vnitřni Lekarství</i> , 2022, 68, 19-25.	0.1	1
1024	Long noncoding RNA SNHG1 silencing accelerates hepatocyte-like cell differentiation of bone marrow-derived mesenchymal stem cells to alleviate cirrhosis via the microRNA-15a/SMURF1/UVRAG axis. <i>Cell Death Discovery</i> , 2022, 8, 77.	2.0	8

#	ARTICLE	IF	CITATIONS
1025	Combining Hepatic and Splenic CT Radiomic Features Improves Radiomic Analysis Performance for Liver Fibrosis Staging. <i>Diagnostics</i> , 2022, 12, 550.	1.3	9
1026	Low Hemoglobin-to-Red Cell Distribution Width Ratio Is Associated with Mortality in Patients with HBV-Related Decompensated Cirrhosis. <i>BioMed Research International</i> , 2022, 2022, 1-6.	0.9	6
1028	Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. <i>Pharmaceutics</i> , 2022, 14, 627.	2.0	1
1029	Sobrevida en pacientes con cirrosis de acuerdo con su etiología. Cohorte retrospectiva. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 24-32.	0.1	1
1030	Pregnancy in women with liver cirrhosis is associated with increased risk for complications: A systematic review and meta-analysis of the literature. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1644-1652.	1.1	7
1031	A Novel Sprague-Dawley Rat Model Presents Improved NASH/NAFLD Symptoms with PEG Coated Vitexin Liposomes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3131.	1.8	5
1032	Evaluation of Liver Fibrosis Using Shear Wave Elastography: An Overview. , 0, , .		0
1033	Prognostic Role of MELD-Lactate in Cirrhotic Patientsâ€™ Short- and Long-Term Prognosis, Stratified by Causes of Cirrhosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-8.	0.8	1
1034	A Meta-Analysis of the Influence of Tumor Necrosis Factor- $\beta$ -308 Gene Polymorphism on Liver Cirrhosis. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-8.	1.1	3
1035	Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleedingâ€™ Long-term follow-up of a randomised control trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	8
1036	Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. <i>International Journal of Hepatology</i> , 2022, 2022, 1-17.	0.4	0
1037	Safe for Mother, Baby, and Graft? Pregnancy After Liver Transplant: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2022, , .	0.3	0
1038	Can Location of Stiffness Measurement Impact Spleen 2-Dimensional Shear Wave Elastography Measurement?. <i>Ultrasound Quarterly</i> , 2022, Publish Ahead of Print, .	0.3	0
1039	Clinical effects of cluster technology optimization and innovations on laparoscopic splenectomy and azygoportal disconnection: a single-center retrospective study with 500 consecutive cases. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 7409-7418.	1.3	1
1040	Prognostic value of albumin-related ratios in HBV-associated decompensated cirrhosis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24338.	0.9	3
1041	Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 833878.	2.2	22
1042	Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora. <i>Frontiers in Pharmacology</i> , 2022, 13, 814871.	1.6	11
1043	Serum Folate deficiency in HCV related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2022, 12, 5025.	1.6	3

#	ARTICLE	IF	CITATIONS
1044	Decellularized Organ-Derived Scaffold Is a Promising Carrier for Human Induced Pluripotent Stem Cells-Derived Hepatocytes. <i>Cells</i> , 2022, 11, 1258.	1.8	6
1045	High C-Reactive Protein-to-Lymphocyte Ratio Is Predictive of Unfavorable Prognosis in HBV-Associated Decompensated Cirrhosis. <i>Laboratory Medicine</i> , 2022, 53, e149-e153.	0.8	2
1046	Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 774335.	1.8	15
1047	Assessment of Three-Phasic CT Scan Findings of Cirrhosis Due to Primary Sclerosing Cholangitis Versus Cryptogenic Cirrhosis. <i>Cureus</i> , 2022, 14, e23956.	0.2	0
1048	Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	4
1049	Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study. <i>Hepatology International</i> , 2022, 16, 658-668.	1.9	7
1050	The value of liver stiffness measured by two-dimensional shear wave elastography for predicting symptomatic posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 150, 110248.	1.2	1
1051	Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G473-G479.	1.6	7
1052	Liver cirrhosis with encapsulating peritoneal sclerosis after 4 years of peritoneal dialysis. <i>Medicine (United States)</i> , 2021, 100, e28350.	0.4	0
1053	Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	0
1054	Differences in complications between hepatitis B-related cirrhosis and alcohol-related cirrhosis. <i>Open Medicine (Poland)</i> , 2021, 17, 46-52.	0.6	3
1055	Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders. <i>Journal of Clinical Medicine</i> , 2021, 10, 5689.	1.0	1
1056	Natural history of NAFLD: knowns and unknowns. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 151-152.	8.2	10
1058	Hemorheological and biochemical study in patients with liver cirrhosis. <i>Physics of Fluids</i> , 2022, 34, 041907.	1.6	1
1059	Suppression of Oxidative Stress and Proinflammatory Cytokines Is a Potential Therapeutic Action of <i>Ficus lepicarpa</i> B. (Moraceae) against Carbon Tetrachloride (CCl <sub>4</sub> )-Induced Hepatotoxicity in Rats. <i>Molecules</i> , 2022, 27, 2593.	1.7	1
1060	Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver fibrosis by activating GSK3 $\beta$ and inhibiting the Wnt3a/ $\beta$ -catenin pathway. <i>Infectious Agents and Cancer</i> , 2022, 17, 17.	1.2	7
1061	Clinical Characteristics and Outcomes of Decompensated Cirrhosis Patients Admitted to Hospitals With Acute Pulmonary Embolisms: A Nationwide Analysis. <i>Cureus</i> , 2022, 14, e24162.	0.2	0
1091	ALDH2 Polymorphism rs671 *1/*2 Genotype is a Risk Factor for the Development of Alcoholic Liver Cirrhosis in Hakka Alcoholics. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4067-4077.	0.8	3

#	ARTICLE	IF	CITATIONS
1092	Decreased diversity of salivary microbiome in patients with stable decompensated cirrhosis.. Hippokratia, 2020, 24, 157-165.	0.3	0
1093	Shugan Huoxue Huayu Fang attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting transforming growth factor- $\beta$ 1/Smad signaling.. Journal of Traditional Chinese Medicine, 2022, 42, 65-72.	0.1	0
1094	Livogrit, a herbal formulation of Boerhavia diffusa, Phyllanthus niruri and Solanum nigrum reverses the thioacetamide induced hepatocellular toxicity in zebrafish model. Toxicology Reports, 2022, 9, 1056-1064.	1.6	3
1095	Serum PPP1CA as a Protein Biomarker for the Diagnosis of Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
1096	A Novel Splenic Vein Flow Volume to the Portal Vein Flow Velocity Index as a Predictor for the Degree of Esophageal Varices in Liver Cirrhosis Patients. Case Reports in Gastroenterology, 2022, 16, 179-185.	0.3	1
1097	Impact of liver cirrhosis on ST-elevation myocardial infarction related shock and interventional management, a nationwide analysis. World Journal of Hepatology, 2022, 14, 766-777.	0.8	0
1098	Construction of PIK3C3 Transgenic Pig and Its Pathogenesis of Liver Damage. Life, 2022, 12, 630.	1.1	1
1099	Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis. Annals of Hepatology, 2023, 28, 100721.	0.6	2
1100	What Makes Cirrhosis Irreversible?â€”Consideration on Structural Changes. Frontiers in Medicine, 2022, 9, 876293.	1.2	0
1101	Focal liver lesions in cirrhosis: Role of contrast-enhanced ultrasonography. World Journal of Radiology, 2022, 14, 70-81.	0.5	2
1102	Comprehensive Analysis of the Differentially Expressed Transcriptome with ceRNA Networks in a Mouse Model of Liver Cirrhosis. Current Bioinformatics, 2022, 17, 510-520.	0.7	2
1103	Cardiovascular manifestation of end-stage liver disease and perioperative echocardiography for liver transplantation: anesthesiologistâ€™s view. Anesthesia and Pain Medicine, 2022, 17, 132-144.	0.5	0
1104	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology and Hepatology, 2022, 7, 755-769.	3.7	34
1105	Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review. Stem Cell Research and Therapy, 2022, 13, 192.	2.4	21
1106	Newly Diagnosed Hepatic Encephalopathy Presenting as Non-convulsive Status Epilepticus: A Case Report and Literature Review. Frontiers in Neurology, 2022, 13, .	1.1	0
1107	Inadequate social support decreases survival in decompensated liver cirrhosis patients. GastroenterologÄa Y HepatologÄa, 2023, 46, 28-38.	0.2	2
1108	Sex is a major effect modifier between body composition and mortality in patients with cirrhosis assessed for liver transplantation. Liver International, 2023, 43, 160-169.	1.9	4
1109	Identifying and Exploring the Candidate Susceptibility Genes of Cirrhosis Using the Multi-Tissue Transcriptome-Wide Association Study. Frontiers in Genetics, 2022, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
1110	Quantitative and qualitative liver CT: imaging feature association with histopathologically confirmed hepatic cirrhosis. <i>Abdominal Radiology</i> , 2022, , .	1.0	1
1111	Epidemic characteristics of alcoholâ€related liver disease in Asia from 2000 to 2020: A systematic review and metaâ€analysis. <i>Liver International</i> , 2022, 42, 1991-1998.	1.9	9
1112	The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study. <i>Frontiers in Medicine</i> , 2022, 9, 872428.	1.2	5
1113	Serum kallistatin as a marker of severity of liver fibrosis in cirrhosis: A cross-sectional observational study. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2129.	0.3	1
1114	Trust Your Gut: The Association of Gut Microbiota and Liver Disease. <i>Microorganisms</i> , 2022, 10, 1045.	1.6	20
1115	Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study. <i>Korean Journal of Internal Medicine</i> , 0, , .	0.7	1
1116	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 1014-1025.	1.8	64
1117	Remimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing Gastroscopy: A Randomized Controlled Study. <i>Medical Science Monitor</i> , 0, 28, .	0.5	6
1118	Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	2
1119	Pathogenesis of Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1492-1513.	0.4	17
1120	Evaluation of Hepatic Hemodynamics (Hepatic Venous Pressure Gradient) During Right Heart Catheterization: A Comprehensive Review. <i>Current Problems in Cardiology</i> , 2022, 47, 101278.	1.1	3
1121	Peripheral endothelial and microvascular damage in liver cirrhosis: a systematic review and metaâ€analysis. <i>Microcirculation</i> , 0, , .	1.0	0
1122	Hepatic function predictive value of hepatic venous waveform versus portal vein velocity in liver cirrhosis. <i>Journal of Medical Ultrasound</i> , 2022, 30, 109.	0.2	1
1123	Liver Stiffness is Reduced to Normal After Successful Renal Transplantation: A Prospective Cohort Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1445-1450.	0.4	2
1124	Focal Nodular Hyperplasia and Focal Nodular Hyperplasiaâ€like Lesions. <i>Radiographics</i> , 2022, 42, 1043-1061.	1.4	15
1125	MRI in liver cirrhosis. , 2022, 1, 23-41.		0
1126	Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 191-206.	1.8	8
1127	Sex Disparities in Outcome of Patients with Alcohol-Related Liver Cirrhosis within the Eurotransplant Networkâ€A Competing Risk Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3646.	1.0	4



#	ARTICLE	IF	CITATIONS
1128	Protective Effect of Mitophagy Regulated by mTOR Signaling Pathway in Liver Fibrosis Associated with Selenium. <i>Nutrients</i> , 2022, 14, 2410.	1.7	10
1129	Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis. <i>Hepatology International</i> , 2022, 16, 936-943.	1.9	3
1130	Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation. <i>Biomedicines</i> , 2022, 10, 1496.	1.4	4
1131	Established Liposome-Coated IMB16-4 Polymeric Nanoparticles (LNPs) for Increasing Cellular Uptake and Anti-Fibrotic Effects In Vitro. <i>Molecules</i> , 2022, 27, 3738.	1.7	2
1132	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
1133	Educational Case: Evaluating a patient with cirrhosis. <i>Academic Pathology</i> , 2022, 9, 100031.	0.7	0
1134	Cirrosis hepática o falla hepática crónica agudizada: definición y clasificación. <i>Repertorio De Medicina Y Cirugia</i> , 2022, 31, 112-122.	0.0	1
1135	Deep Learning-Based Automated Assessment of Hepatic Fibrosis on Magnetic Resonance Images and Non-Image Data. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1136	Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation?. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	1
1137	Crocetin Protected Human Hepatocyte LO2 Cell From TGF- $\beta$ -Induced Oxygen Stress and Apoptosis but Promoted Proliferation and Autophagy via AMPK/m-TOR Pathway. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
1138	Assessing liver fibrosis distribution through liver elasticity estimates obtained using a biomechanical model of respiratory motion with magnetic resonance elastography. <i>Physics in Medicine and Biology</i> , 2022, 67, 155005.	1.6	3
1139	Use of Non-selective Beta blockers in Decompensated Cirrhosis and ACLF. <i>Current Hepatology Reports</i> , 2022, 21, 29-36.	0.4	1
1140	Predictive value of serum bile acids as metabolite biomarkers for liver cirrhosis: a systematic review and meta-analysis. <i>Metabolomics</i> , 2022, 18, .	1.4	7
1141	Heterogeneity and Function of Kupffer Cells in Liver Injury. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
1142	The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7151.	1.8	14
1143	Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2001-2008.	0.5	6
1144	Plasticity of monocytes and macrophages in cirrhosis of the liver. <i>Frontiers in Network Physiology</i> , 0, 2, .	0.8	2
1145	Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100529.	2.6	8



#	ARTICLE	IF	CITATIONS
1146	Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs, 2022, 31, 825-842.	1.9	0
1147	Simvastatin is Efficacious in Treating Cirrhosis. Journal of Clinical Gastroenterology, 2022, 56, e303-e312.	1.1	2
1148	Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients. PLoS ONE, 2022, 17, e0271020.	1.1	4
1149	Igf2bp2 knockdown improves CCl4-induced liver fibrosis and TGF- $\beta$ 2-activated mouse hepatic stellate cells by regulating Tgfr1. International Immunopharmacology, 2022, 110, 108987.	1.7	9
1150	Materials and extracellular matrix rigidity highlighted in tissue damages and diseases: Implication for biomaterials design and therapeutic targets. Bioactive Materials, 2023, 20, 381-403.	8.6	11
1151	Trends in Mortality and Health Care Burden of Cirrhotic Decompensation in Hospitalized Patients. Journal of Clinical Gastroenterology, 2023, 57, 743-747.	1.1	1
1152	Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages. Stem Cell Research and Therapy, 2022, 13, .	2.4	35
1153	Platelets, mean platelet volume, lymphocytes, leukocytes, and ratios of them altered in patients with hepatitis B virus-related decompensated cirrhosis. Precision Medical Sciences, 0, .	0.1	0
1154	Lack of Nogo-B expression ameliorates PPAR $\beta$ 3 deficiency-aggravated liver fibrosis by regulating TLR4-NF- $\kappa$ B-TNF- $\alpha$ axis and macrophage polarization. Biomedicine and Pharmacotherapy, 2022, 153, 113444.	2.5	9
1155	A novel nomogram based on the nutritional risk screening 2002 score to predict survival in hepatocellular carcinoma treated with transarterial chemoembolization. Nutricion Hospitalaria, 2022, , .	0.2	1
1156	Morbimortality Associated with Liver Cirrhosis in Peru: An Ecological Analysis for the Period of 2004-2016. International Journal of Environmental Research and Public Health, 2022, 19, 9036.	1.2	1
1157	The importance of natural chalcones in ischemic organ damage: Comprehensive and bioinformatic analysis review. Journal of Food Biochemistry, 2022, 46, .	1.2	1
1158	Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 633-647.	1.8	3
1159	Comparing 2D-shear wave to transient elastography for the evaluation of liver fibrosis in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2022, 34, 961-966.	0.8	2
1160	Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy. Frontiers in Oncology, 0, 12, .	1.3	1
1161	Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China. World Journal of Gastroenterology, 2022, 28, 4417-4430.	1.4	2
1162	Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart. Cureus, 2022, , .	0.2	1
1164	Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Brazilian Journal of Infectious Diseases, 2022, 26, 102697.	0.3	3

#	ARTICLE	IF	CITATIONS
1165	The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2068-2073.	0.7	2
1166	Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury. <i>World Journal of Gastroenterology</i> , 2022, 28, 4133-4151.	1.4	3
1167	Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. <i>Trauma Surgery and Acute Care Open</i> , 2022, 7, e000936.	0.8	3
1168	Efficacy of interventional radiology in the management of portal hypertension: A narrative review. <i>Medicine (United States)</i> , 2022, 101, e30018.	0.4	3
1169	Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH). <i>Current Problems in Cardiology</i> , 2022, 47, 101351.	1.1	7
1170	Survival Fate of Hepatic Stem/Progenitor and Immune Cells in a Liver Fibrosis/Cirrhosis Animal Model and Clinical Implications. , 0, , .		0
1171	TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	4
1172	A novel fast kilovoltage switching dual-energy computed tomography technique with deep learning: Utility for non-invasive assessments of liver fibrosis. <i>European Journal of Radiology</i> , 2022, 155, 110461.	1.2	3
1173	D-Dimer-to-Albumin Ratio: A Novel Indicator to Predict Poor Outcomes in Patients with HBV-Associated Decompensated Cirrhosis. <i>BioMed Research International</i> , 2022, 2022, 1-6.	0.9	2
1174	Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats. <i>Life Sciences</i> , 2022, 308, 120966.	2.0	4
1175	Human Serum Albumin Infusion in Liver Cirrhosis. , 2022, , 113-125.		0
1176	Cognitive Impairment and Cirrhosis in Older Patients: A Systematic Review. <i>Gerontology and Geriatric Medicine</i> , 2022, 8, 233372142211225.	0.8	0
1177	Efficacy of partial embolization of splenic artery in patients after hemorrhage of portal genesis. <i>Klinichna Khirurgiia</i> , 2022, 88, 47-52.	0.0	0
1178	MiRNAs in liver fibrosis: new targets and opportunities for therapy. , 2022, , 363-372.		0
1179	A preoperative model based on gadobenate-enhanced MRI for predicting microvascular invasion in hepatocellular carcinomas (â‰¥ 5 cm). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1180	Severe Stenosis of Mitral Bioprosthetic Valve Thrombosis in a Patient with HCV-Related Cirrhosis and Duodenal Variceal Bleeding: The Deadly Triad. <i>Clinics and Practice</i> , 2022, 12, 686-691.	0.6	1
1181	Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges. <i>Stem Cells Translational Medicine</i> , 2022, 11, 900-911.	1.6	12
1182	Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1

#	ARTICLE	IF	CITATIONS
1183	Global cirrhosis prevalence trends and attributable risk factors—an ecological study using data from 1990–2019. <i>Liver International</i> , 2022, 42, 2791-2799.	1.9	4
1184	Association of hydroxysteroid 11-beta dehydrogenase 1 polymorphisms with chronic liver fibrosis and the occurrence of hepatocellular carcinoma in a Han Chinese population. <i>International Journal of Transgender Health</i> , 2022, 15, 951-959.	1.1	0
1185	Microbe-bridged disease-metabolite associations identification by heterogeneous graph fusion. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	3
1186	A deep learning approach for detecting liver cirrhosis from volatolomic analysis of exhaled breath. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1187	Global research trends in the field of liver cirrhosis from 2011 to 2020: A visualised and bibliometric study. <i>World Journal of Gastroenterology</i> , 2022, 28, 4909-4919.	1.4	2
1188	<i>Salvia miltiorrhiza</i> in thorax and abdominal organ fibrosis: A review of its pharmacology. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1189	Timing of endoscopic intervention in patients with cirrhosis with acute variceal haemorrhage (TEACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0.8	0.8	0
1190	Improvement of gut microbiome and intestinal permeability following splenectomy plus pericardial devascularization in hepatitis B virus-related cirrhotic portal hypertension. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1191	VariScreen secures the screening of high-risk varices in patients with hepatitis B virus-related cirrhosis beyond Baveno VI criteria. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	1
1192	On the Core Prescriptions and Their Mechanisms of Traditional Chinese Medicine in Hepatitis B, Liver Cirrhosis, and Liver Cancer Treatment. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	6
1193	Flow Resistance Analysis of Clinically Significant Portal Hypertension in Patients with Liver Cirrhosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-7.	0.8	0
1194	Machine learning models including insulin resistance indexes for predicting liver stiffness in United States population: Data from NHANES. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1195	Possibility of Liver Cancer Treatment By Nanoformulation of Phenolic Phytochemicals. <i>Current Nanomedicine</i> , 2022, 12, 108-125.	0.2	1
1196	Spleen and Liver Stiffness Evaluation by ARFI Imaging: A Reliable Tool for a Short-Term Monitoring of Portal Hypertension?. <i>International Journal of Hepatology</i> , 2022, 2022, 1-14.	0.4	0
1197	Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study. <i>European Radiology</i> , 2023, 33, 1653-1667.	2.3	3
1198	Radiological psoas muscle parameters as a reliable tool for detection of sarcopenia and prediction of short-term survival in liver cirrhosis. <i>Reports of Morphology</i> , 2022, 28, 5-13.	0.0	0
1199	Human stem cells for decompensated cirrhosis in adults. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
1200	β-Blockers to Prevent Decompensation of Cirrhosis in Compensated Patients With Clinically Significant Portal Hypertension. , 2022, , 407-418.		0

#	ARTICLE	IF	CITATIONS
1201	Epidemiological, Clinical, Paraclinical, Etiological and Therapeutic Aspects of Liver Cirrhosis in the Hepato-Gastroenterology Department of the Hospital Aristide Le Dantec in Dakar. <i>Open Journal of Gastroenterology</i> , 2022, 12, 317-323.	0.1	0
1202	Efficacy and predictors to response of octreotide and midodrine combination in patients with hepatorenal syndrome. , 2022, 1, 69.		0
1203	Clinical Stages and Ordinal Outcomes in Portal Hypertension. , 2022, , 15-28.		0
1204	Diagn�sticos de enfermagem em pacientes com cirrose hep�tica em um servi�o hospitalar de emerg�ncia. <i>HU Revista</i> , 0, 48, 1-8.	0.3	0
1205	Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 403-411.	0.6	3
1206	Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis. <i>World Journal of Clinical Cases</i> , 0, 10, 10984-10996.	0.3	1
1207	Global, regional, and national burden and quality of care index of liver cirrhosis by cause from global burden of disease 1990�2019. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 119-128.	1.4	2
1208	Liver Function�How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. <i>Journal of Personalized Medicine</i> , 2022, 12, 1657.	1.1	4
1209	Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis. <i>JHEP Reports</i> , 2023, 5, 100619.	2.6	5
1210	Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1211	Hepatic perfusion as a new predictor of prognosis and mortality in critical care patients with acute-on-chronic liver failure. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1212	The role of microRNAs on the pathogenesis, diagnosis and management of portal hypertension in patients with chronic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 941-951.	1.4	0
1213	Liver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches. <i>Livers</i> , 2022, 2, 372-386.	0.8	1
1214	Covered transjugular intrahepatic portosystemic stent-shunt <i>vs</i> large volume paracentesis in patients with cirrhosis: A real-world propensity score-matched study. <i>World Journal of Clinical Cases</i> , 0, 10, 11313-11324.	0.3	0
1215	Validation of Baveno VI and Expanded-Baveno VI Criteria for predicting gastroesophageal varices in patients with alcoholic and non-alcoholic fatty liver disease. <i>Acta Gastro-Enterologica Belgica</i> , 2022, 85, 321-329.	0.4	1
1216	Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII � an update. <i>Digestive and Liver Disease</i> , 2023, 55, 326-335.	0.4	6
1217	Liver Cirrhosis Stage Prediction Using Machine Learning: Multiclass Classification. <i>Lecture Notes in Networks and Systems</i> , 2023, , 109-129.	0.5	0
1218	Computed tomography perfusion in liver and spleen for hepatitis B virus-related portal hypertension: A correlation study with hepatic venous pressure gradient. <i>World Journal of Gastroenterology</i> , 0, 28, 6068-6077.	1.4	4

#	ARTICLE	IF	CITATIONS
1219	A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis. <i>Annals of Medicine</i> , 2022, 54, 3200-3209.	1.5	4
1220	MiRNA/mRNA network topology in hepatitis virus B-related liver cirrhosis reveals miR-20a-5p/340-5p as hubs initiating fibrosis. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	1
1221	Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1222	Bioactive coumarin-derivative esculetin decreases hepatic stellate cell activation via induction of cellular senescence via the PI3K-Akt-GSK3 $\beta$ pathway. <i>Food Bioscience</i> , 2022, 50, 102164.	2.0	3
1223	Development and validation of a nomogram for esophagogastric variceal bleeding in liver cirrhosis: A cohort study in 1099 cases. <i>Journal of Digestive Diseases</i> , 2022, 23, 597-609.	0.7	5
1224	Prediction of esophageal and gastric varices rebleeding for cirrhotic patients based on deep learning. <i>Biomedical Signal Processing and Control</i> , 2023, 81, 104420.	3.5	0
1225	ESOPHAGEAL VARICES AND ASSOCIATED FACTORS IN CIRRHOTIC PATIENTS WITH HEPATITIS C. <i>Journal of Ayub Medical College, Abbottabad: JAMC</i> , 2022, 34, 838-841.	0.1	1
1226	Elevated calprotectin levels are associated with mortality in patients with acute decompensation of liver cirrhosis. <i>World Journal of Hepatology</i> , 0, 14, 1964-1976.	0.8	4
1228	In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 559-571.	2.3	8
1229	Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF- $\beta$ 2/Smad pathway suppression in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 642, 192-200.	1.0	1
1230	Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research</i> , 2022, 15, 325-333.	0.4	1
1231	Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1232	Contrast-enhanced ultrasonography for the management of portal hypertension in cirrhosis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1233	Event dependent overall survival in the population-based LIFE-Adult-Study. <i>PLoS ONE</i> , 2022, 17, e0278069.	1.1	1
1234	Coumaric acid from <i>M. polymorphum</i> extracts reverses the activated state of hepatic stellate cells (GRX) and inhibits their proliferation by decreasing the p53/p21 pathway. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	0
1235	Correlation between serum liver fibrosis markers and early gastroesophageal varices among patients with compensated liver cirrhosis: a cross-sectional analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	2
1236	A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 359-369.	1.4	3
1237	Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1

#	ARTICLE	IF	CITATIONS
1238	Spleen stiffness: a predictive factor of dismal prognosis in liver cirrhosis. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 121-129.	0.4	2
1239	Complement C3 Facilitates Stratification of Stages of Chronic Hepatitis B and Signifies Development of Acute-on-Chronic Liver Failure in Acute Decompensated Cirrhosis. <i>Advances in Therapy</i> , 0, , .	1.3	0
1240	Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 482-495.	4.5	10
1241	Therapeutic interventions of acute and chronic liver disorders: A comprehensive review. <i>World Journal of Hepatology</i> , 0, 15, 19-40.	0.8	2
1242	Clinical Guideline on Perioperative Management of Patients with Advanced Chronic Liver Disease. <i>Life</i> , 2023, 13, 132.	1.1	3
1243	SRF/MRTF and liver cirrhosis: pathologic associations. <i>Journal of Digestive Diseases</i> , 0, , .	0.7	1
1244	Profiles of Clinical and Liver Function Test of Hepatitis B and C Patients with Liver Cirrhosis. <i>JUXTA Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga</i> , 2023, 14, 30-35.	0.0	0
1245	Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1246	Correlation of Platelet Count with Grading of Esophageal Varices in Cirrhotic Patients. <i>Open Journal of Gastroenterology</i> , 2023, 13, 12-27.	0.1	0
1247	Updates on Quantitative MRI of Diffuse Liver Disease: A Narrative Review. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	2
1248	The Development of Symbolic Expressions for the Detection of Hepatitis C Patients and the Disease Progression from Blood Parameters Using Genetic Programming-Symbolic Classification Algorithm. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 574.	1.3	2
1249	A review of edible plant-derived natural compounds for the therapy of liver fibrosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 133-152.	0.8	2
1250	Chronic Liver Disease: Liver Cirrhosis and Diagnostic Features. , 0, , 30-33.		0
1251	Insights on drug and gene delivery systems in liver fibrosis. <i>Asian Journal of Pharmaceutical Sciences</i> , 2023, 18, 100779.	4.3	6
1252	Liver cirrhosis: relationship between fibrosis-associated hepatic morphological changes and portal hemodynamics using four-dimensional flow magnetic resonance imaging. <i>Japanese Journal of Radiology</i> , 2023, 41, 625-636.	1.0	2
1253	Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis. <i>JHEP Reports</i> , 2023, 5, 100688.	2.6	2
1254	Potential Clinical Applications of Ozone Therapy in Dental Specialties—A Literature Review, Supported by Own Observations. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2048.	1.2	3
1255	Identification of Potential Hub Genes Related to Aflatoxin B1, Liver Fibrosis and Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. <i>Biology</i> , 2023, 12, 205.	1.3	3



#	ARTICLE	IF	CITATIONS
1256	Inadequate social support decreases survival in decompensated liver cirrhosis patients. <i>Gastroenterology</i> & <i>Hepatology</i> (English Edition), 2023, 46, 28-38.	0.0	0
1257	The Role of Statins in the Prevention and Treatment of Complications Related to Cir-rhosis. <i>Advances in Clinical Medicine</i> , 2023, 13, 2320-2324.	0.0	0
1258	p53 and Myofibroblast Apoptosis in Organ Fibrosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6737.	1.8	1
1259	SNAIL-activated long non-coding RNA LINC01711 promotes hepatic fibrosis cell proliferation and migration by regulating XYLT1. <i>Genomics</i> , 2023, 115, 110597.	1.3	0
1260	Biosensors integrated 3D organoid/organ-on-a-chip system: A real-time biomechanical, biophysical, and biochemical monitoring and characterization. <i>Biosensors and Bioelectronics</i> , 2023, 231, 115285.	5.3	13
1261	Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses. <i>Advances in Therapy</i> , 2023, 40, 1494-1529.	1.3	4
1262	Characterization and microRNA Expression Analysis of Serum-Derived Extracellular Vesicles in Severe Liver Injury from Chronic HBV Infection. <i>Life</i> , 2023, 13, 347.	1.1	1
1263	Identification of key genes related to immune infiltration in cirrhosis via bioinformatics analysis. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1265	Breath Biopsy to Identify Exhaled Volatile Organic Compounds Biomarkers for Liver Cirrhosis Detection. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	4
1266	Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
1267	Analysis of Immune and Inflammatory Microenvironment Characteristics of Noncancer End-Stage Liver Disease. <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 86-97.	0.5	0
1268	Protective role of resveratrol against VCM-induced hepatotoxicity in male wistar rats. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1270	Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1271	Decompensation as initial presentation in patients with liver cirrhosis is associated with an increased risk of future decompensation and mortality. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 900-907.	0.6	1
1272	Baseline ALBI Grade Predicts Benefits After Splenectomy for Cirrhotic Patients with Hypersplenism. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 1130-1140.	0.9	1
1273	The potential value of serum GP73 in the ancillary diagnosis and grading of liver cirrhosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 95-102.	0.6	0
1274	Differential metabolites in cirrhotic patients with hepatitis B and muscle mass loss. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
1275	Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 915-922.	0.6	2



#	ARTICLE	IF	CITATIONS
1276	Factors predicting mortality in patients with alcoholic liver cirrhosis visiting the emergency department. <i>Medicine (United States)</i> , 2023, 102, e33074.	0.4	0
1277	GL-V9 ameliorates liver fibrosis by inhibiting TGF- $\beta$ 2/smad pathway. <i>Experimental Cell Research</i> , 2023, 425, 113521.	1.2	4
1278	Numerical prediction of portal hypertension by a hydrodynamic blood flow model combining with the fractal theory. <i>Journal of Biomechanics</i> , 2023, 150, 111504.	0.9	4
1280	Combined model with acoustic radiation force impulse to rule out high-risk varices in HBV-related cirrhosis with viral suppression. <i>Digestive and Liver Disease</i> , 2023, 55, 1062-1071.	0.4	2
1281	Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy. <i>Journal of Virus Eradication</i> , 2023, 9, 100319.	0.3	1
1282	Staging liver fibrosis in patients with chronic hepatitis B using two-dimensional shear wave elastography based on histopathological findings: a prospective multicenter study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, 13, 2376-2387.	1.1	0
1283	Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension. <i>JHEP Reports</i> , 2023, 5, 100722.	2.6	2
1284	Traditional Chinese medicine targets on hepatic stellate cells for the treatment of hepatic fibrosis: A mechanistic review. , 2023, 2, 16-31.		3
1285	FAT10 Silencing Prevents Liver Fibrosis through Regulating SIRT1 Expression in Hepatic Stellate Cells. <i>International Journal of Medical Sciences</i> , 2023, 20, 557-565.	1.1	0
1286	Associations of gallbladder and gallstone parameters with clinical outcomes in patients with cirrhosis. <i>Journal of Translational Internal Medicine</i> , 2023, .	1.0	1
1287	Extracellular volume fraction obtained by dual-energy CT depicting the etiological differences of liver fibrosis. <i>Abdominal Radiology</i> , 0, , .	1.0	0
1288	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 721-732.	4.5	131
1289	Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 1177-1187.	0.9	2
1290	EASIX Is an Accurate and Easily Available Prognostic Score in Critically Ill Patients with Advanced Liver Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2553.	1.0	0
1291	Analysis of Complications and Risk Factors Other than Bleeding before and after Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2023, 2023, 1-12.	0.8	1
1292	The effects of prognostic factors on transplant and mortality of patients with end-stage liver disease using Markov multistate model. <i>Journal of Research in Medical Sciences</i> , 2023, 28, 28.	0.4	0
1293	Association Between MRI-Assessed Patterns of Connectome Gradient and Gene Expression Profiles in Two Independent Patient Cohorts With Hepatitis B Virus-Related Cirrhosis. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	0
1295	Fat mitigation strategies to improve image quality of radial 4D flow MRI in obese subjects. <i>Magnetic Resonance in Medicine</i> , 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
1296	Mori fructus aqueous extracts attenuates liver injury by inhibiting ferroptosis via the Nrf2 pathway. Journal of Animal Science and Biotechnology, 2023, 14, .	2.1	5
1297	Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue. Nature Biomedical Engineering, 2023, 7, 1437-1454.	11.6	9
1298	Therapeutic role of FNDC5/irisin in attenuating liver fibrosis via inhibiting release of hepatic stellate cell-derived exosomes. Hepatology International, 0, , .	1.9	2
1299	Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis. Life, 2023, 13, 991.	1.1	2
1300	Differentiation between alcohol-associated cirrhosis and hepatitis B-associated cirrhosis based on hepatic complications and psychological symptoms. Journal of Research in Medical Sciences, 2023, 28, 37.	0.4	0
1301	Vitamin D supply and its relationship with nutritional status and survival in patients with liver cirrhosis. Reports of Vinnytsia National Medical University, 2023, 27, 79-85.	0.0	0
1302	A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients. Journal of Hepatocellular Carcinoma, 0, Volume 10, 659-671.	1.8	4
1303	Computed tomography perfusion in differentiating portal hypertension: A correlation study with hepatic venous pressure gradient. World Journal of Gastrointestinal Surgery, 0, 15, 664-673.	0.8	0
1370	Licorice. , 2023, , 763-787.		0
1385	Hepatitis C Virus. , 2022, , 1-28.		0
1415	Noninvasive diagnosis of liver cirrhosis: qualitative and quantitative imaging biomarkers. Abdominal Radiology, 0, , .	1.0	0